[go: up one dir, main page]

WO2011059610A1 - Composés de benzènesulfonamide-thiazole et oxazole - Google Patents

Composés de benzènesulfonamide-thiazole et oxazole Download PDF

Info

Publication number
WO2011059610A1
WO2011059610A1 PCT/US2010/051890 US2010051890W WO2011059610A1 WO 2011059610 A1 WO2011059610 A1 WO 2011059610A1 US 2010051890 W US2010051890 W US 2010051890W WO 2011059610 A1 WO2011059610 A1 WO 2011059610A1
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
mmol
formula
compound
chloro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2010/051890
Other languages
English (en)
Inventor
Jerry Leroy Adams
Thomas Faitg
Jiri Kasparec
Xin Peng
Jeffrey Ralph
Tara Renae Rheault
Alex Gregory Waterson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline LLC
Original Assignee
GlaxoSmithKline LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline LLC filed Critical GlaxoSmithKline LLC
Priority to EP10830388.4A priority Critical patent/EP2498608A4/fr
Publication of WO2011059610A1 publication Critical patent/WO2011059610A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Definitions

  • the present invention relates to benzene sulfonamide thiazole and oxazole compounds, compositions containing the same, as well as processes for the preparation and methods of using such compounds and compositions.
  • RTKs Receptor tyrosine kinases
  • Ras-Raf-MEK-ERK kinase pathway Downstream of the several RTKs lie several signaling pathways, among them is the Ras-Raf-MEK-ERK kinase pathway. It is currently understood that activation of Ras GTPase proteins in response to growth factors, hormones, cytokines, etc. stimulates phosphorylation and activation of Raf kinases. These kinases then phosphorylate and activate the intracellular protein kinases MEK1 and MEK2, which in turn phosphorylate and activate other protein kinases, ERK1 and 2. This signaling pathway, also known as the mitogen-activated protein kinase (MAPK) pathway or cytoplasmic cascade, mediates cellular responses to growth signals.
  • MAPK mitogen-activated protein kinase
  • the ultimate function of this is to link receptor activity at the cell membrane with modification of cytoplasmic or nuclear targets that govern cell proliferation, differentiation, and survival. Mutations in various Ras GTPases and the B-Raf kinase have been identified that can lead to sustained and constitutive activation of the MAPK pathway, ultimately resulting in increased cell division and survival. As a consequence of this, these mutations have been strongly linked with the establishment, development, and progression of a wide range of human cancers.
  • the biological role of the Raf kinases, and specifically that of B-Raf, in signal transduction is described in Davies, H., et al., Nature (2002) 9:1 -6; Garnett, M.J.
  • central nervous system tumors including primary CNS tumors such as
  • glioblastomas astrocytomas and ependymomas
  • secondary CNS tumors i.e., metastases to the central nervous system of tumors originating outside of the central nervous system
  • colorectal cancer including large intestinal colon carcinoma (Yuen et al
  • leukemias Garnett et al., Cancer Cell (2004) supra, particularly acute lymphoblastic leukemia (Garnett et al., Cancer Cell (2004) supra and Gustafsson et al Leukemia (2005) 19(2) 310- 312)
  • AML acute myelogenous leukemia
  • AML acute myelogenous leukemia
  • myelodysplastic syndromes Christiansen et al Leukemia (2005) supra
  • chronic myelogenous leukemia Mizuchi et al Biochem. Biophys. Res. Commun.
  • pancreatic cancer Ishimura et al Cancer Lett. (2003) 199(2) 169-173
  • pituitary adenoma (De Martino et al J. Endocrinol. Invest. (2007) 30(1 ) RC1 - 3)
  • prostate cancer Cho et al Int. J. Cancer (2006) 1 19(8) 1858-1862
  • renal cancer Nagy et al Int. J. Cancer (2003) 106(6) 980-981
  • Raf family kinases By virtue of the role played by the Raf family kinases in these cancers and exploratory studies with a range of preclinical and therapeutic agents, including one selectively targeted to inhibition of B-Raf kinase activity (King A.J ., et al., (2006) Cancer Res. 66:1 1 100-1 1 105), it is generally accepted that inhibitors of one or more Raf family kinases will be useful for the treatment of such cancers or other condition associated with Raf kinase.
  • B-Raf has also been implicated in other conditions, including cardio-facio cutaneous syndrome (Rodriguez-Viciana et al Science (2006) 31 1 (5765) 1287-1290) and polycystic kidney disease (Nagao et al Kidney Int. (2003) 63(2) 427-437).
  • the invention encompasses the compounds of formula (I)
  • W is selected from -O- and -S-;
  • R is selected from ci-c6alkyl, haloalkyl, and C 3-c 6 cycloalkyl;
  • R 3 is selected from Het1 , pyridinyl, and ci-c6alkyl optionally substituted with -
  • R 4 is selected from H, -NH-R 7 and -CH 2 -R 7 ;
  • R 5 and R 6 are independently selected from H, F, and CI;
  • R 7 is selected from H, C i-c6alkylene-R 8 , and -co-c3alkylene-Het1 , and ci-c6alkyl optionally substituted with -( C o-c6alkylene-(OH) m ) n ;
  • R 8 is selected from haloalkyl-, CN, OH, and -SO 2 -ci-c3alkyl;
  • each Het1 is a 5-6 membered heterocycle having 1 or 2 heteroatoms selected from N and O and optionally substituted with 1 or 2 substituents
  • each m is 1 or 2;
  • each n is 1 or 2;
  • compositions comprising the compounds, methods of treating susceptible neoplasms with the compounds, processes for preparing the compounds, and use of the compounds in the treatment of susceptible neoplasms.
  • W is selected from -O- and -S-;
  • R 1 is selected from ci-c6alkyl, haloalkyl, and c3-c6cycloalkyl;
  • R 3 is selected from Het1 , pyridinyl, and ci-c6alkyl optionally substituted with
  • R 4 is selected from H, -NH-R 7 and -CH 2 -R 7 ;
  • R 5 and R 6 are independently selected from H, F, and CI;
  • R 7 is selected from H, C i-c6alkylene-R 8 , and -co-c3alkylene-Het1 , and ci-c6alkyl optionally substituted with -( C o-c6alkylene-(OH) m ) n ;
  • R 8 is selected from haloalkyl-, CN, OH, and -SO 2 -ci-c3alkyl;
  • each Het1 is a 5-6 membered heterocycle having 1 or 2 heteroatoms selected from N and O and optionally substituted with 1 or 2 substituents
  • each m is 1 or 2;
  • each n is 1 or 2;
  • R 1 is selected from ci-c6alkyl and haloalkyl.
  • R 3 is a 5-6 membered heterocycle having 1 or 2 heteroatoms selected from N and O and optionally substituted with 1 or 2 substituents independently selected from ci-c3alkyl, -SO2-ci-c3alkyl, and -ci-c3alkylene-OH.
  • compounds of formula (I) as in the first aspect wherein R 1 is selected from ci-c6alkyl and haloalkyl.
  • R 3 is selected from
  • R 1 is selected from ci-c6alkyl, haloalkyl, and C 3-c 6 cycloalkyl;
  • R 3 is selected from Het1 , pyridinyl, and ci-c6alkyl optionally substituted with -
  • R 4 is selected from H, -NH-R 7 and -CH 2 -R 7 ;
  • R 5 and R 6 are independently selected from H, F, and CI;
  • R 7 is selected from H, C i-c6alkylene-R 8 , and -co-c3alkylene-Het1 , and ci-c6alkyl optionally substituted with -( C o-c6alkylene-(OH) m ) n ;
  • R 8 is selected from haloalkyl-, CN, OH, and -SO2-ci-c3alkyl;
  • each Het1 is a 5-6 membered heterocycle having 1 or 2 heteroatoms selected from N and O and optionally substituted with 1 or 2 substituents
  • each m is 1 or 2;
  • each n is 1 or 2;
  • compounds of formula (la) as in the second aspect wherein R 3 is a 5-6 membered heterocycle having 1 or 2 heteroatoms selected from N and O and optionally substituted with 1 or 2 substituents independently selected from ci-c3alkyl, -SO2-ci-c3alkyl, and -ci c3alkylene-OH.
  • R 3 is selected from
  • R1 is selected from propyl and tri-flouro-propyl.
  • R 1 is selected from ci-c6alkyl, haloalkyl, and C 3-c6cycloalkyl;
  • R 3 is selected from Het1 , pyridinyl, and ci-c6alkyl optionally substituted with
  • R 4 is selected from -NH-R 7 and -CH 2 -R 7 ;
  • R 5 and R 6 are independently selected from H, F, and CI;
  • R 7 is selected from H, C i-c6alkylene-R 8 , and -co-c3alkylene-Het1 , and ci-c6alkyl optionally substituted with -(co-c6alkylene-(OH) m ) n ;
  • R 8 is selected from haloalkyl-, CN, OH, and -SO2-ci-c3alkyl;
  • each Het1 is a 5-6 membered heterocycle having 1 or 2 heteroatoms selected from N and O and optionally substituted with 1 or 2 substituents
  • each m is 1 or 2;
  • each n is 1 or 2;
  • R 3 is a 5-6 membered heterocycle having 1 or 2 heteroatoms selected from N and O and optionally substituted with 1 or 2 substituents independently selected from ci-c3alkyl, -SO2-ci-c3alkyl, and -ci-c3alkylene-OH.
  • R 3 is selected from
  • a pharmaceutical composition comprising a compound of formula (I) (including any particular sub-generic formula described herein) or a pharmaceutically acceptable salt thereof.
  • the pharmaceutical composition further comprises one or more of pharmaceutically acceptable carriers, diluents or excipients.
  • a method of treating a susceptible neoplasm in a mammal in need thereof comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) (including any particular sub-generic formula described herein) or a pharmaceutically acceptable salt thereof.
  • Susceptible neoplasms include e.g., Barret's adenocarcinoma; billiary tract carcinomas; breast cancer; cervical cancer; cholangiocarcinoma; central nervous system tumors including primary CNS tumors such as glioblastomas, astrocytomas (e.g., glioblastoma multiforme) and ependymomas, and secondary CNS tumors (i.e., metastases to the central nervous system of tumors originating outside of the central nervous system); colorectal cancer including large intestinal colon carcinoma; gastric cancer; carcinoma of the head and neck including squamous cell carcinoma of the head and neck; hematologic cancers including leukemias and lymphomas such as acute lymphoblastic leukemia, acute myelogenous leukemia (AML), myelodysplastic syndromes, chronic myelogenous leukemia, Hodgkin's lymphoma, non-Hodgkin's lymphoma,
  • erythroleukemia hepatocellular carcinoma
  • lung cancer including small cell lung cancer and non-small cell lung cancer
  • ovarian cancer endometrial cancer
  • pancreatic cancer pituitary adenoma
  • prostate cancer renal cancer
  • sarcoma skin cancers including melanomas
  • thyroid cancers include melanomas
  • a method of treating a susceptible neoplasm in a mammal, particularly a human, in need thereof comprising administering to the mammal (e.g. human) a
  • a method of treating breast cancer, cholangiocarcinoma, colorectal cancer, melanoma, non-small cell lung cancer, ovarian cancer, or thyroid cancer in a mammal, particularly a human, in need thereof, comprising administering to the mammal (e.g. human) a therapeutically effective amount of a compound of formula (Ilia)
  • R 10 is halo or thiomethyl
  • a process for preparing a compound of formula (I) or a pharmaceutically acceptable salt thereof comprises reacting a compound of formula (XVIII):
  • a compound of formula (I), (including any particular sub-generic formula described herein) or a pharmaceutically acceptable salt thereof for use in therapy is provided.
  • a compound of formula (I) (including any particular sub-generic formula described herein) or a pharmaceutically acceptable salt thereof for use in the treatment of a susceptible neoplasm (e.g., Barret's adenocarcinoma; bil Nary tract carcinomas; breast cancer; cervical cancer; cholangiocarcinoma; central nervous system tumors including primary CNS tumors such as glioblastomas, astrocytomas (e.g., glioblastoma multiforme) and ependymomas, and secondary CNS tumors (i.e., metastases to the central nervous system of tumors originating outside of the central nervous system); colorectal cancer including large intestinal colon carcinoma; gastric cancer; carcinoma of the head and neck including squamous cell carcinoma of the head and neck; hematologic cancers including leukemias and lymphomas such as acute lymphoblastic leukemia, acute myelogenous leukemia (AML), myel
  • AML acute my
  • cholangiocarcinoma cholangiocarcinoma, colorectal cancer, melanoma, non-small cell lung cancer, ovarian cancer, or thyroid cancer in a mammal (e.g., human) in need thereof.
  • a susceptible neoplasm e.g., Barret's adenocarcinoma; billiary tract carcinomas; breast cancer; cervical cancer; cholangiocarcinoma; central nervous system tumors including primary CNS tumors such as glioblastomas, astrocytomas (e.g., glioblastoma multiforme) and ependymomas, and secondary CNS tumors (i.e., metastases to the central nervous system of tumors originating outside of the central nervous system); colorectal cancer including large intestinal colon carcinoma; gastric cancer; carcinoma of the head and neck including squamous cell carcinoma of the head and neck; hematologic cancers including leukemias and lymphomas such as acute lymphoblastic leukemia,
  • a susceptible neoplasm e.g., Barret's adenocarcinoma; billiary tract carcinomas; breast cancer; cervical cancer; cholangiocarcinoma; central nervous system tumors including primary
  • hepatocellular carcinoma including small cell lung cancer and non-small cell lung cancer; ovarian cancer; endometrial cancer; pancreatic cancer; pituitary adenoma; prostate cancer; renal cancer; sarcoma; skin cancers including melanomas; and thyroid cancers
  • a mammal e.g., human
  • a compound of formula (I) (including any particular sub-generic formula described herein) or a pharmaceutically acceptable salt thereof, in the preparation of a medicament for use in the treatment of breast cancer, cholangiocarcinoma, colorectal cancer, melanoma, non-small cell lung cancer, ovarian cancer, or thyroid cancer in a mammal (e.g., human) in need thereof.
  • a pharmaceutical composition comprising a compound of formula (I) (including any particular sub-generic formula described herein) or a pharmaceutically acceptable salt thereof for use in the treatment of a susceptible neoplasm (e.g., Barret's adenocarcinoma; billiary tract carcinomas; breast cancer; cervical cancer; cholangiocarcinoma; central nervous system tumors including primary CNS tumors such as glioblastomas, astrocytomas (e.g., glioblastoma multiforme) and ependymomas, and secondary CNS tumors (i.e., metastases to the central nervous system of tumors originating outside of the central nervous system); colorectal cancer including large intestinal colon carcinoma; gastric cancer; carcinoma of the head and neck including squamous cell carcinoma of the head and neck; hematologic cancers including leukemias and lymphomas such as acute lymphoblastic leukemia, acute myelogenous le
  • a pharmaceutical composition comprising a compound of formula (I) (including any particular sub-generic formula described herein) or a pharmaceutically acceptable salt thereof for use in the treatment of breast cancer, colorectal cancer,
  • melanoma non-small cell lung cancer, ovarian cancer, or thyroid cancer in a mammal (e.g., human) in need thereof.
  • Raf family kinase refers to Raf kinases including A- Raf, B-Raf and c-Raf (also known as Raf-1 ). Unless distinguished herein, the term refers to both wildtype and mutant variations thereof.
  • compound(s) of formula (I) means any compound having the structural formula (I) as defined by the variable definitions provided, possible solvates, including hydrates thereof, and amorphous and crystal forms, including one or more polymorphic forms and mixtures thereof.
  • the compounds may be in the form of a racemic mixture, or one or more isomerically enriched or pure stereoisomers, including enantiomers and diastereomers thereof.
  • “compound(s) of formula (I)” includes the racemic form as well as the enriched or pure enantiomers and diastereomers.
  • Enantiomerically enriched or pure compounds will be designated using conventional nomenclature, including the designations +, -, R, S, d, I, D and L, according to the predominant isomer present.
  • a compound of the invention contains an alkenyl or alkenylene group, cis (E) and trans (Z) isomerism may also occur. In such embodiments,
  • compound(s) of the invention means a compound of formula (I) (as defined above) in any version, i.e., as the free base or as a pharmaceutically acceptable salt thereof.
  • the compound as any version may be in any form, including amorphous or crystalline forms, specific polymorphic forms, solvates, including hydrates (e.g., mono-, di- and hemi- hydrates), and mixtures of various forms. Intermediates may also be present as salts.
  • alkyl refers to linear or branched hydrocarbon chains having from 1 to 8 carbon atoms, unless a different number of atoms is specified.
  • alkyl as used herein include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, n-pentyl, sec-butyl, isobutyl, and tert-butyl.
  • alkyl and variations thereof (i.e., "Ci -4 alkyl”) is intended to independently describe each member of the genus.
  • alkylene refers to linear or branched divalent hydrocarbon chains containing from 1 to 8 carbon atoms, unless a different number of atoms is specified.
  • alkylene as used herein include, but are not limited to, methylene, ethylene, propylene, butylene, and isobutylene.
  • alkylene and variations thereof (i.e., “Ci-3alkylene") is intended to be
  • alkenyl refers to linear or branched hydrocarbon chains having from 2 to 8 carbon atoms, unless a different number of atoms is specified, and at least one and up to three carbon-carbon double bonds.
  • alkenyl examples include, but are not limited to ethenyl and propenyl.
  • alkenyl and variations thereof (i.e., "C2 -4 alkenyl") is intended to independently describe each member of the genus.
  • cycloalkyl refers to a saturated monocyclic carbocyclic ring having from 3 to 8 carbon atoms, unless a different number of atoms is specified.
  • Cycloalkyl includes by way of example cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl.
  • Preferred cycloalkyl groups include substituted and unsubstituted C3-6cycloalkyl.
  • cycloalkyl and variations thereof (i.e., "C3-6cycloalkyl) is intended to independently describe each member of the genus.
  • halo and “halogen” are synonymous and refer to fluoro, chloro, bromo and iodo. In particular embodiments, “halo” refers to fluoro and chloro.
  • haloalkyi refers to an alkyl, as defined above, substituted by one or more halogen atoms, fluoro, chloro, bromo or iodo. According to one embodiment, haloalkyi defineds an alkyl substituted by one to three fluoro atoms. Where the haloalkyi group has less than 8 carbon atoms, the number of carbon atoms in the group is indicated as, for example, "haloCi-3alkyl", which indicates that the haloalkyi group has 1 , 2 or 3 carbon atoms.
  • haloalkyi examples include, but are not limited to
  • haloalkyi and variations thereof (i.e., “haloCi-3alkyl") is intended to independently describe each member of the genus.
  • heterocycle and “heterocyclic” are synonymous and refer to monocyclic saturated or unsaturated non-aromatic groups, having from 4 to 6 members (unless a different number of members is specified) and including 1 , 2, or 3 heteroatoms selected from N, O and S, unless a different number of heteroatoms is specified.
  • the heterocycle includes 2 or more heteroatoms
  • the heteroatoms may be the same or different and are independently selected from N, O and S.
  • the compound of formula (I) includes two or more heterocyclic groups
  • the heterocyclic groups may be the same or different and are independently selected.
  • heterocyclic groups include but are not limited to tetrahydrofuran, dihydropyran, tetrahydropyran, pyran, thietane, 1 ,4-dioxane, 1 ,3-dioxane, 1 ,3-dioxalane, piperidine, piperazine, pyrrolidine, morpholine, thiomorpholine, thiazolidine, oxazolidine, tetrahydrothiopyran, tetrahydrothiophene and the like.
  • heterocycle and variations thereof (i.e., "N-heterocycle) is intended to independently describe each member of the genus.
  • N-heterocycle refers to monocyclic saturated or unsaturated non-aromatic groups having from 4 to 6 members, including at least one N and optionally 1 or 2 additional heteroatoms selected from N, O and S, unless a different number of additional heteroatoms is specified.
  • additional heteroatoms is meant 1 or 2 heteroatoms in addition to the N already specified in the N-heterocycle ring.
  • the heteroatoms may be the same or different and are independently selected from N, O and S.
  • N- heterocycles include both groups bound through the N of the N-heterocycle and groups bound through a C or S of the N-heterocycle.
  • the N-heterocyclic groups may be the same or different and are independently selected.
  • Examples of N-heterocycles include piperidine, piperazine, pyrrolidine, morpholine, thiomorpholine and the like.
  • heteroaryl refers to aromatic, monocyclic groups having 5 or 6 members (unless a different number of members is specified) including 1 , 2 or 3 heteroatoms selected from N, O and S, unless a different number of heteroatoms is specified.
  • the heteroaryl includes 2 or more heteroatoms, the heteroatoms may be the same or different and are independently selected from N, O and S.
  • the compound of formula (I) includes two or more heteroaryl groups, the heteroaryl groups may be the same or different and are independently selected.
  • heteroaryl groups include but are not limited to furan, thiophene, pyrrole, imidazole, pyrazole, triazole, tetrazole, thiazole, oxazole, isoxazole, oxadiazole, thiadiazole, isothiazole, pyridine, pyridazine, pyrazine, pyrimidine, and triazine.
  • heteroaryl and variations thereof (i.e., "N-heteroaryl”) is intended to independently describe each member of the genus.
  • N-heteroaryl refers to aromatic, monocyclic groups having 5 or 6 members (unless a different number of members is specified) including at least one N and optionally 1 or 2 additional heteroatoms selected from N, O and S, unless a different number of heteroatoms is specified.
  • additional heteroatoms is meant 1 or 2 heteroatoms in addition to the N already specified in the N-heteroaryl ring.
  • the heteroaryl includes 1 or more additional heteroatoms, the heteroatoms may be the same or different and are independently selected from N, O and S.
  • N- heteroaryls include both groups bound through the N of the N-heteroaryl and groups bound through a C or S of the N-heteroaryl.
  • the N-heteroaryl groups may be the same or different and are independently selected.
  • Examples of N-heteroaryls include pyrrole, imidazole, pyrazole, thiazole, isoxazole, pyridine, pyridazine, pyrazine, pyrimidine and triazine.
  • the term "members" (and variants thereof e.g., “membered") in the context of heterocyclic and heteroaryl groups refers to the total number of ring atoms, including carbon and heteroatoms N, O and/or S.
  • an example of a 6-membered heterocyclic ring is piperidine and an example of a 6-membered heteroaryl ring is pyridine.
  • optionally substituted means unsubstituted groups or rings (e.g., cycloalkyl, heterocycle, and heteroaryl rings) and rings substituted with one or more specified substituents.
  • the invention encompasses the compounds of formula (I)
  • W is selected from -O- and -S-;
  • R 1 is selected from ci-c6alkyl, haloalkyl, and C 3-c 6 cycloalkyl;
  • R 3 is selected from Het1 , pyridinyl, and ci-c6alkyl optionally substituted with - (co-c6alkylene-(OH) m ) n ;
  • R 4 is selected from H, -NH-R 7 and -CH 2 -R 7 ;
  • R 5 and R 6 are independently selected from H, F, and CI;
  • R 7 is selected from H, C i-c6alkylene-R 8 , and -co-c3alkylene-Het1 , and ci-c6alkyl optionally substituted with -( C o-c6alkylene-(OH) m ) n ;
  • R 8 is selected from haloalkyl-, CN, OH, and -SO2-ci-c3alkyl;
  • each Het1 is a 5-6 membered heterocycle having 1 or 2 heteroatoms selected from N and O and optionally substituted with 1 or 2 substituents
  • each m is 1 or 2;
  • each n is 1 or 2;
  • compositions comprising the compounds, methods of treating susceptible neoplasms with the compounds, processes for preparing the compounds, and use of the compounds in the treatment of susceptible neoplasms.
  • W is selected from -O- and -S-;
  • R 1 is selected from ci-c6alkyl, haloalkyl, and c3-c6cycloalkyl;
  • R 3 is selected from ci-c6alkyl optionally substituted with -( C o-c6alkylene-
  • R 4 is selected from H, -NH-R 7 and -CH 2 -R 7 ;
  • R 5 and R 6 are independently selected from H, F, and CI;
  • R 7 is selected from H, C i-c6alkylene-R 8 , and -co-c3alkylene-Het1 , and ci-c6alkyl optionally substituted with -( C o-c6alkylene-(OH) m ) n ;
  • R 8 is selected from haloalkyl-, CN, OH, and -SO2-ci-c3alkyl;
  • each Het1 is a 5-6 membered heterocycle having 1 or 2 heteroatoms selected from N and O and optionally substituted with 1 or 2 substituents
  • each m is 1 or 2;
  • each n is 1 or 2;
  • R 1 is a linear or branched ci-c6alkyl. More particularly, R1 is advantageously selected from methyl, ethyl, propyl, isopropyl, butyl, isobutyl, and tert-butyl. In another aspect, there is provided compounds of formula (I) as in the first aspect wherein R 1 is advantageously a haloalkyl. More particularly, R 1 is advantageously selected from tri-fluoroethylene and tri-fluoropropylene.
  • R 1 is selected from propyl and tri-flouro-propylene.
  • R 3 is a 5-6 membered heterocycle having 1 or 2 heteroatoms selected from N and O and optionally substituted with 1 or 2 substituents independently selected from ci-c3alkyl, -SO2-ci-c3alkyl, and -ci-c3alkylene-OH.
  • R 3 is selected from
  • R 1 is selected from ci-c6alkyl, haloalkyl, and c 3 -c 6 cycloalkyl;
  • R 3 is selected from Het1 , pyridinyl, and ci-c6alkyl optionally substituted with -
  • R 4 is selected from H, -NH-R 7 and -CH 2 -R 7 ;
  • R 5 and R 6 are independently selected from H, F, and CI;
  • R 7 is selected from H, C i-c6alkylene-R 8 , and -co-c3alkylene-Het1 , and ci-c6alkyl optionally substituted with -( C o-c6alkylene-(OH) m ) n ;
  • R 8 is selected from haloalkyl-, CN, OH, and -SO2-ci-c3alkyl;
  • each Het1 is a 5-6 membered heterocycle having 1 or 2 heteroatoms selected from N and O and optionally substituted with 1 or 2 substituents
  • each m is 1 or 2;
  • each n is 1 or 2;
  • R 1 is a linear or branched ci-c6alkyl. More particul R1 is advantageously selected from methyl, ethyl, propyl, isopropyl, butyl, isobutyl, and tert-butyl.
  • R 1 is advantageously a haloalkyl. More particularly, R 1 is advantageously selected from tri-fluoroethylene and tri-fluoropropylene.
  • R 1 is selected from propyl and tri-flouro-propyl.
  • R 3 is a 5-6 membered heterocycle having 1 or 2 heteroatoms selected from N and O and optionally substituted with 1 or 2 substituents independently selected from ci-c3alkyl, -SO 2 -ci-c3alkyl, and - C i- c3alkylene-OH.
  • compounds of formula (la) as in the second aspect wherein R 4 is -CH 2 -R 7 .
  • R 4 is selected from ethyl, 1 -propanol, and 2-methyl-2-butanol.
  • R 1 is selected from ci-c6alkyl, haloalkyl, and C 3-c 6 cycloalkyl;
  • R 3 is selected from Het1 , pyridinyl, and ci-c6alkyl optionally substituted with - (co-c6alkylene-(OH) m ) n ;;
  • R 4 is selected from -NH-R 7 and -CH 2 -R 7 ;
  • R 5 and R 6 are independently selected from H, F, and CI;
  • R 7 is selected from H, C i-c6alkylene-R 8 , and -co-c3alkylene-Het1 , and ci-c6alkyl optionally substituted with -( C o-c6alkylene-(OH) m ) n ;
  • R 8 is selected from haloalkyl-, CN, OH, and -SO2-ci-c3alkyl;
  • each Het1 is a 5-6 membered heterocycle having 1 or 2 heteroatoms selected from N and O and optionally substituted with 1 or 2 substituents
  • R 1 is a linear or branched ci-c6alkyl . More particularly, R1 is advantageously selected from methyl, ethyl, propyl, isopropyl, butyl, isobutyl, and tert-butyl.
  • R 1 is advantageously a haloalkyl. More particularly, R 1 is advantageously selected from tri-fluoroethylene and tri-fluoropropylene. In another aspect, there is provided compounds of formula (Ic) as in the third aspect, wherein R 1 is selected from propyl and tri-flouro-propyl.
  • R 3 is a 5-6 membered heterocycle having 1 or 2 heteroatoms selected from N and O and optionally substituted with 1 or 2 substituents independently selected from ci-c3alkyl, -SO2-ci-c3alkyl, and -ci-c3alkylene-OH.
  • R 3 is selected from
  • the compounds of formula (I) may be utilized as a pharmaceutically acceptable salt version thereof.
  • the pharmaceutically acceptable salts of the compounds of formula (I) include conventional salts formed from pharmaceutically acceptable (i.e., non-toxic) inorganic or organic acids or bases as well as quaternary ammonium salts.
  • Representative salts include the following: acetate, benzenesulfonate, benzoate, bicarbonate, bisulfate, bitartrate, borate, bromide, calcium edetate, camsylate, carbonate, chloride, clavulanate, citrate, dihydrochloride, edetate, edisylate, estolate, esylate, ethanol amine, fumarate, gluceptate, gluconate, glutamate, glycollylarsanilate, hexylresorcinate, hydrabamine, hydrobromide, hydrochloride, hydroxynaphthoate, iodide, isethionate, lactate, lactobionate, laurate, malate, maleate, mandelate, mesylate (methanesulfonate), methylbromide, methylnitrate, methylsulfate, monopotassium maleate, mucate, napsylate, nitrate
  • the compound of formula (I) is in the form of the free base.
  • the compound of formula (I) is in the form of the mesylate salt.
  • the compound of formula (I) is in the form of the sulfate salt.
  • the compound of formula (I) is in the form of the hydrochloride salt.
  • the compound of formula (I) is in the form of the sodium salt.
  • Certain salt versions of the compounds may be solvates, particularly hydrates.
  • the compound of formula (I) or a pharmaceutically acceptable salt thereof is in the form of a mono-, di-, tri- or hemi- hydrate.
  • Raf inhibitor a Raf family kinases
  • B- Raf inhibitor B- Raf inhibitor
  • Compounds of the invention may be Raf inhibitors and optionally also inhibit one or more ErbB family kinases (i.e., EGFR, ErbB2 and ErbB4). Certain compounds of the invention may inhibit B-Raf and also inhibit one or more ErbB family kinases (i.e., EGFR, ErbB2 and ErB4).
  • Some compounds of the invention may be selective inhibitors of Raf family kinases ("selective Raf inhibitor"), meaning that preferential inhibition of one or more Raf family kinases is significantly greater than that of any number of other kinases, for example by a factor of 5-fold or more.
  • the present invention is not limited to compounds which are selective inhibitors of one or more Raf family kinases rather, the present invention expressly contemplates that certain compounds of the invention may possess activity against multiple kinases, including kinases other than Raf family kinases.
  • particular compounds of the invention may possess activity against multiple other kinases, including but not limited to EGFR, ErbB2, ErbB4, IGF-1 R, IR, IRR, Src, VEGFR, PDGFR, Met, Lyn, Lck, Alk5, Aurora A and B, JNK, Syk, p38, BTK, FAK, Abl, CK1 .
  • a Raf inhibitor is a compound that exhibits a plC 5 o of greater than about 6 against at least one Raf family kinase in the Raf inhibition enzyme assay described below and/or an IC 5 o of not greater than about 5 ⁇ potency against at least one cell line that expresses mutated B-Raf kinase (e.g., A375P, Colo205, HT-29, SK-MEL-3, SK-MEL-28) in the methylene blue and/or the CellTiter-Glo cellular proliferation assays described below.
  • mutated B-Raf kinase e.g., A375P, Colo205, HT-29, SK-MEL-3, SK-MEL-28
  • a Raf inhibitor refers to a compound of the invention that exhibits a plC 5 o of greater than about 6.5 against at least one Raf family kinase in the Raf inhibition enzyme assay described below and an IC 50 of not greater than about 500nM potency against at least one cell line that expresses mutated B-Raf kinase in the methylene blue and/or the CellTiter- Glo cellular proliferation assays described below.
  • a "B-Raf inhibitor” refers to a compound of the invention that exhibits a plC 5 o of greater than about 6.5 against B-Raf (including B-Raf mutants) in the Raf inhibition enzyme assay described below and an IC 5 o of not greater than about 500nM potency against at least one cell line that expresses mutated B- Raf kinase in the methylene blue and/or the CellTiter-Glo cellular proliferation assay described below.
  • the present invention provides compounds for use in medical therapy in a mammal, e.g., a human, in need thereof.
  • the present invention provides methods for the treatment of several conditions in a mammal, in need thereof, all of which comprise the step of administering a therapeutically effective amount of a compound of the invention. All methods described herein are applicable to mammals, and particularly to humans.
  • treatment refers to alleviating the specified condition, eliminating or reducing the symptoms of the condition, slowing or eliminating the progression, invasion, or metastatic spread of the condition and preventing or delaying the reoccurrence of the condition in a previously afflicted subject.
  • the present invention further provides use of the compounds of the invention for the preparation of a medicament for the treatment of several conditions in a mammal (e.g., human) in need thereof.
  • the present invention provides compounds for use in the treatment of a condition mediated by at least one Raf family kinases (e.g., B- Raf) in a mammal in need thereof.
  • the present invention provides a method for treating a condition mediated by at least one Raf family kinase (e.g., B- Raf) in a mammal (e.g., a human) in need thereof, which method comprises administering to the mammal a therapeutically effective amount of the compound of the invention.
  • the invention provides compounds for use in regulating, modulating, binding or inhibiting one or more Raf family kinases (e.g., B-Raf) in a mammal.
  • the invention also provides methods of
  • Raf family kinase e.g., B-Raf
  • regulating, modulating, binding, or inhibiting at least one Raf family kinase refers to regulating, modulating, binding or inhibiting the activity of at least one Raf family kinase, as well as regulating, modulating, binding or inhibiting overexpression of an upstream regulator of at least one Raf family kinase in order to inhibit the cellular potency of its signaling ability.
  • the invention provides compounds for use in the treatment of a condition mediated by inappropriate activity of one or more Raf family kinases (e.g., B-Raf), or an upstream activator of one or more Raf family kinases in a mammal.
  • the invention further provides methods for the treatment of a condition mediated by inappropriate activity of one or more Raf family kinases (particularly B-Raf), in a mammal in need thereof, comprising administering to the mammal, a therapeutically effective amount of a compound of the invention.
  • the present invention provides the use of a compound of the invention for the preparation of a medicament for the treatment of a condition mediated by inappropriate activity of one or more Raf family kinases (particularly B-Raf), in a mammal.
  • a condition mediated by inappropriate activity of one or more Raf family kinases includes neoplasms.
  • inappropriate activity is meant Raf family kinase activity that deviates from the expected activity for that kinase or for an upstream activator of that kinase in a particular mammal.
  • the inappropriate activity of a Raf family kinase may arise from one or more of A-Raf, B-Raf or c-Raf or an upstream activator of a Raf family kinase.
  • Inappropriate Raf family kinase activity may take the form of, for instance, an abnormal increase in activity, or an aberration in the timing and/or control of Raf family kinase activity.
  • Such inappropriate activity may result, for example, from overexpression or mutation of the kinase, upstream activator, receptor or ligand leading to inappropriate or uncontrolled activation of the corresponding kinase or receptor.
  • unwanted Raf family kinase activity may reside in an abnormal source, such as a neoplasm.
  • the level of Raf family kinase activity does not need to be abnormal to be considered inappropriate in the case where the activity derives from an abnormal source including, but not limited to, upstream activators (e.g., activated mutant Ras GTPases) or neoplasm.
  • upstream activators e.g., activated mutant Ras GTPases
  • inappropriate Raf family kinase activity not resulting from mutation or overexpression of a Raf family kinase inappropriate activity of a Ras GTPase may result from mutation or overexpression of Ras GTPase, for example the G13D mutation in KRas2, and may lead to overactivation of the MAPK pathway mediated by Raf family kinase activity.
  • the present invention provides compounds for use in the treatment of a condition which directly or indirectly results from a mutation of a Raf family kinase or overexpression of a Raf family kinase, or a mutation of an upstream activator of a Raf family kinase or overexpression of an upstream activator of a Raf family kinase in a mammal in need thereof.
  • the present invention provides methods for the treatment of a condition which directly or indirectly results from mutation of a Raf family kinase or
  • overexpression of a Raf family kinase or a mutation of an upstream activator of a Raf family kinase or overexpression of an upstream activator of a Raf family kinase in a mammal in need thereof, comprising administering to the mammal, a therapeutically effective amount of a compound of the invention.
  • the present invention provides the use of a compound of the invention for the preparation of a medicament for the treatment of a condition which directly or indirectly results from mutation of a Raf family kinase or overexpression of a Raf family kinase, or a mutation of an upstream activator of a Raf family kinase or overexpression of an upstream activator of a Raf family kinase in a mammal.
  • Conditions which are mediated by at least one Raf family kinase, and particularly conditions mediated by inappropriate activity of one or more Raf family kinases, including those which directly or indirectly result from mutation of a Raf family kinase, overexpression of a Raf family kinase, or mutation of an upstream activator of a Raf family kinase or overexpression of an upstream activator of a Raf family kinase are known in the art and include but are not limited to neoplasms.
  • Compounds of the invention may also be used in the treatment of conditions attenuated by inhibition of a Raf family kinase (particularly B-Raf). Further provided are methods for treating a condition attenuated by inhibition of a Raf family kinase (particularly B-Raf) in a mammal in need thereof, comprising administering to the mammal, a therapeutically effective amount of a compound of the invention. Also provided is the use of a compound of the invention for the preparation of a medicament for the treatment of a condition attenuated by inhibition of a Raf family kinase (particularly B-Raf) in a mammal.
  • Conditions attenuated by inhibition of a Raf family kinase include but are not limited to neoplasms. Accordingly, compounds of the invention may be used in the treatment of a neoplasm, particularly a susceptible neoplasm (a cancer or tumor) in a mammal.
  • the present invention also provides a method for treating a neoplasm, particularly a susceptible neoplasm in a mammal in need thereof, which method comprises administering to the mammal a therapeutically effective amount of the compound of the invention.
  • the invention also provides the use of a compound of the invention for the preparation of a medicament for the treatment of neoplasm, particularly a susceptible neoplasm, in a mammal.
  • “Susceptible neoplasm” as used herein refers to neoplasms which are susceptible to treatment by a kinase inhibitor and particularly neoplasms that are susceptible to treatment by a Raf inhibitor.
  • Neoplasms which have been associated with inappropriate activity of one or more Raf family kinases and particularly neoplasms which are exhibit mutation of a Raf family kinase, overexpression of a Raf family kinase, or mutation of an upstream activator of a Raf family kinase or overexpression of an upstream activator of a Raf family kinase, and are therefore susceptible to treatment with an Raf inhibitor are known in the art, and include both primary and metastatic tumors and cancers. See, Catalogue of Somatic Mutations in Cancer (COSMIC), the Wellcome Trust Sanger Institute,
  • central nervous system tumors including primary CNS tumors such as
  • glioblastomas astrocytomas (including glioblastoma multiforme) and ependymomas
  • secondary CNS tumors i.e., metastases to the central nervous system of tumors originating outside of the central nervous system
  • colorectal cancer including large intestinal colon carcinoma
  • carcinoma of the head and neck including squamous cell carcinoma of the head and neck;
  • hematologic cancers including leukemias and lymphomas such as acute
  • lymphoblastic leukemia acute myelogenous leukemia (AML), myelodysplastic syndromes, chronic myelogenous leukemia, Hodgkin's lymphoma, non-Hodgkin's lymphoma, megakaryoblastic leukemia, multiple myeloma and erythroleukemia;
  • lung cancer including small cell lung cancer and non-small cell lung cancer; ovarian cancer;
  • endometrial cancer pancreatic cancer
  • skin cancers including melanomas
  • the susceptible neoplasm is a neoplasm which exhibits a mutation in BRaf.
  • the present invention provides a method for the treatment of any of Barret's adenocarcinoma; billiary tract carcinomas; breast cancer; cervical cancer; cholangiocarcinoma; central nervous system tumors including primary CNS tumors such as glioblastomas, astrocytomas (e.g., glioblastoma multiforme) and ependymomas, and secondary CNS tumors (i.e., metastases to the central nervous system of tumors originating outside of the central nervous system); colorectal cancer including large intestinal colon carcinoma; gastric cancer; carcinoma of the head and neck including squamous cell carcinoma of the head and neck; hematologic cancers including leukemias and lymphomas such as acute lymphoblastic leukemia, acute myelogenous leukemia (AML), myelodysplastic syndromes, chronic myelogenous leukemia, Hodgkin's lymphoma, non-Hodgkin's lymphom
  • the method comprises administering a therapeutically effective amount of a compound of the invention to the mammal (e.g., human).
  • the present invention provides a method for treating breast cancer, cholangiocarcinoma, colorectal cancer, melanoma, non-small cell lung cancer, ovarian cancer, or thyroid cancer, or any subset thereof. In one particular embodiment, the present invention provides a method for treating cholangiocarcinoma, colorectal cancer, melanoma, or thyroid cancer, or any subset thereof.
  • the present invention provides a method for treating melanoma in a mammal (e.g., human) in need thereof.
  • the method comprises administering to the mammal (e.g. human) a therapeutically effective amount of a compound of formula (I).
  • the compound is selected from
  • the present invention also provides the a compound of formula (I) for use in the treatment of Barret's adenocarcinoma; bill iary tract carcinomas; breast cancer; cervical cancer; cholangiocarcinoma; central nervous system tumors including primary CNS tumors such as glioblastomas, astrocytomas (e.g., glioblastoma multiforme) and ependymomas, and secondary CNS tumors (i.e., metastases to the central nervous system of tumors originating outside of the central nervous system); colorectal cancer including large intestinal colon carcinoma; gastric cancer; carcinoma of the head and neck including squamous cell carcinoma of the head and neck; hematologic cancers including leukemias and lymphomas such as acute lymphoblastic leukemia, acute myelogenous leukemia (AML), myelodysplastic syndromes, chronic myelogenous leukemia, Hodgkin's lymphoma, non-Ho
  • the present invention further provides the use of a compound of formula (I) for the preparation of a medicament for the treatment of Barret's
  • adenocarcinoma billiary tract carcinomas; breast cancer; cervical cancer; cholangiocarcinoma; central nervous system tumors including primary CNS tumors such as glioblastomas, astrocytomas (e.g., glioblastoma multiforme) and ependymomas, and secondary CNS tumors (i.e., metastases to the central nervous system of tumors originating outside of the central nervous system); colorectal cancer including large intestinal colon carcinoma; gastric cancer; carcinoma of the head and neck including squamous cell carcinoma of the head and neck; hematologic cancers including leukemias and lymphomas such as acute lymphoblastic leukemia, acute myelogenous leukemia (AML), myelodysplastic syndromes, chronic myelogenous leukemia, Hodgkin's lymphoma, non-Hodgkin's lymphoma, megakaryoblastic leukemia, multiple myeloma and erythroleuk
  • tumors may metastasize from a first or primary locus of tumor to one or more other body tissues or sites.
  • metastases to the central nervous system i.e., secondary CNS tumors
  • the brain i.e., brain metastases
  • tumors and cancers such as breast, lung, melanoma, renal and colorectal.
  • neoplasm in a subject includes use for and treatment of the primary neoplasm, tumor or cancer, and where appropriate, also the use for and treatment of metastases (i.e., metastatic tumor growth) as well.
  • the susceptible neoplasm is colorectal cancer and the invention provides compounds for use in the treatment of colorectal cancer in a mammal (e.g., human) and the use of such compounds for the preparation of a medicament for the treatment of colorectal cancer in a mammal (e.g., human).
  • the susceptible neoplasm is melanoma
  • the invention provides compounds for use in the treatment of melanoma in a mammal (e.g., human) and the use of such compounds for the preparation of a medicament for the treatment of melanoma in a mammal (e.g., human).
  • the susceptible neoplasm is cholangiocarcinoma
  • the invention provides compounds for use in the treatment of
  • cholangiocarcinoma in a mammal e.g., human
  • a mammal e.g., human
  • use of such compounds for the preparation of a medicament for the treatment of cholangiocarcinoma in a mammal (e.g., human).
  • the susceptible neoplasm is thyroid cancer
  • the invention provides compounds for use in the treatment of thyroid cancer in a mammal (e.g., human) and the use of such compounds for the preparation of a medicament for the treatment of thyroid cancer in a mammal (e.g., human).
  • the susceptible neoplasm is breast cancer and the invention provides compounds for use in the treatment of breast cancer in a mammal (e.g., human) and the use of such compounds for the preparation of a medicament for the treatment of breast cancer in a mammal (e.g., human).
  • the susceptible neoplasm is ovarian cancer and the invention provides compounds for use in the treatment of ovarian cancer in a mammal (e.g., human) and the use of such compounds for the preparation of a medicament for the treatment of ovarian cancer in a mammal (e.g., human).
  • the susceptible neoplasm is non-small cell lung cancer, and the invention provides compounds for use in the treatment of non-small cell lung cancer in a mammal (e.g., human) and the use of such compounds for the preparation of a medicament for the treatment of non- small cell lung cancer in a mammal (e.g., human).
  • the compounds of the invention can be used alone in the treatment of each of the foregoing conditions or can be used to provide additive or potentially synergistic effects with certain existing chemotherapies, radiation, biological or immunotherapeutics (including monoclonal antibodies) and vaccines.
  • the compounds of the invention may be useful for restoring effectiveness of certain existing chemotherapies and radiation and or increasing sensitivity to certain existing chemotherapies and/or radiation.
  • the compounds of the invention may also be used in the treatment of other conditions attenuated by inhibition of a Raf family kinase, such as cardio-facio cutaneous syndrome and polycystic kidney disease.
  • the present invention provides a method for treating a susceptible neoplasm in a mammal in need thereof comprising the steps of:
  • the activating mutation present in the coding sequence for BRAF results in a BRAF having an amino acid substitution selected from the group consisting of R462I, I463S, G464V, G464E, G466A, G466E, G466V, G469A, G469E, D594V, F595L, G596R, L597V, L597R, T599I, V600E, V600D, V600K, V600R, T1 19S, and K601 E. See, for example, Figure 2 of Halilovic and Solvit (2008) Current Opinion in Pharmacology 8:419-26.
  • the present invention provides a method for treating a susceptible neoplasm in a mammal in need thereof comprising the steps of:
  • step (c) administering a therapeutically effective amount of a compound of the present invention to the mammal selected in step (b).
  • the V600E amino acid substitution in B-Raf is described, for example, in Kumar et al. (2004) J Invest Dermatol. 122(2):342-8. This mutation commonly results from a T1799A mutation in the coding sequence for human B-Raf. Accordingly, in one embodiment of the present invention, the step of analyzing a sample from said neoplasm to determine whether a mutation encoding a V600E amino acid substitution is present in the coding sequence for B-Raf is performed by determining whether the coding sequence for B-Raf in cells of the neoplasm contains the T1799A mutation.
  • the neoplasm may be selected from Barret's adenocarcinoma; billiary tract carcinomas; breast cancer; cervical cancer; cholangiocarcinoma; central nervous system tumors including primary CNS tumors such as glioblastomas, astrocytomas (e.g., glioblastoma multiforme) and ependymomas, and secondary CNS tumors (i.e., metastases to the central nervous system of tumors originating outside of the central nervous system); colorectal cancer including large intestinal colon carcinoma; gastric cancer; carcinoma of the head and neck including squamous cell carcinoma of the head and neck; hematologic cancers including leukemias and lymphomas such as acute lymphoblastic leukemia, acute myelogenous leukemia (AML), myelodysplastic syndromes, chronic myelogenous leukemia, Hodgkin's lymphoma, non- Hodgkin's lymphoma, megakaryoblastic le
  • the neoplasm is selected from breast cancer, cholangiocarcinoma, colorectal cancer, melanoma, non-small cell lung cancer, ovarian cancer, and thyroid cancer.
  • the neoplasm is melanoma.
  • the mammal is a human.
  • the sample of the neoplasm to be analyzed for the presence of B-raf activating mutations can be derived from a variety of sources including, but not limited to, single cells, a collection of cells, tissue, cell culture, bone marrow, blood, or other bodily fluids.
  • the tissue or cell source may include a tissue biopsy sample, a cell sorted population, cell culture, or a single cell. In selecting a sample, the percentage of the sample that constitutes neoplastic cells should be considered.
  • the sample from the neoplasm is fixed using a preservative prior to analyzing for the presence of an activating mutation.
  • the step of analyzing a sample from the neoplasm to determine whether an activating mutation is present in the coding sequence for B-Raf in cells of said neoplasm may be performed using any method known in the art.
  • the coding sequence for B-raf in cells of the sample may be analyzed to determine if it contains a mutation which results in the expression of activated B-Raf.
  • Methods for detecting such mutations are well known in the art. See, for example, Whitcombe et al. (1999) Nature Biotechnology 17:804-7, Gibson (2006) Clinica Chimica Acta 363: 32-47, Kim and Misra
  • activating mutations in B-Raf may be identified by directly detecting the activated B-raf protein using an agent (e.g. an antibody) that selectively binds activated B-raf.
  • an agent e.g. an antibody
  • therapeutically effective amount means an amount of a compound of the invention which is sufficient, in the subject to which it is administered, to elicit a biological or medical response of a cell culture, tissue, system, mammal (including human) that is being sought, for instance, by a researcher or clinician.
  • the term also includes within its scope amounts effective to enhance normal physiological function. For example, a
  • a therapeutically effective amount of a compound of the invention for the treatment of a condition mediated by at least one Raf family kinase is an amount sufficient to treat the condition in the particular subject.
  • a therapeutically effective amount of a compound of the invention for the treatment of a susceptible neoplasm is an amount sufficient to treat the particular susceptible neoplasm in the subject.
  • a therapeutically effective amount of a compound of the invention is an amount sufficient to regulate, modulate, bind or inhibit at least one Raf family kinase. More particularly, in such embodiment, the
  • therapeutically effective amount of a compound of the invention is an amount sufficient to regulate, modulate, bind or inhibit B-Raf.
  • the precise therapeutically effective amount of the compounds of the invention will depend on a number of factors. There are variables inherent to the compounds including, but not limited to, the following: molecular weight, inhibitory activity at the target kinase, absorption, bioavailability, distribution in the body, tissue penetration, half-life, metabolism, protein binding, and excretion. These variables determine what dose of compound needs to be administered in order to inhibit the target kinase by a sufficient percentage and for a sufficient amount of time to have the desired effect on the condition being treated (e.g., neoplasm). In general, the goal will be to inhibit the target kinase by 50% or more for as long as possible. The duration of drug exposure will be limited only by the compound half-life, and side effects from treatment requiring cessation of dosing. The amount of compound
  • the compound of the invention will be given for treatment in the range of 0.01 to 30 mg/kg body weight of recipient (mammal) per day or per dose or per cycle of treatment and more usually in the range of 0.1 to 10 mg/kg body weight per day or per dose or per cycle of treatment.
  • the actual amount per day or per dose or per cycle of treatment would usually be from 1 to 2000 mg and this amount may be given in a single or multiple doses per day or per dose or per cycle of treatment.
  • Dosing regimens may vary significantly and will be determined and altered based on clinical experience with the compound. The full spectrum of dosing regimens may be employed ranging from continuous dosing (with daily doses) to intermittent dosing.
  • a therapeutically effective amount of a pharmaceutically acceptable salt of a compound of formula (I) may be determined as a proportion of the
  • the invention further provides a pharmaceutical composition comprising a compound of the invention.
  • the pharmaceutical composition may further comprise one or more pharmaceutically acceptable carriers, diluents, and/or excipients.
  • the carrier(s), diluent(s) and/or excipient(s) must be acceptable in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.
  • a process for the preparation of a pharmaceutical formulation including admixing a compound of the invention with one or more
  • compositions may be presented in unit dose forms containing a predetermined amount of active ingredient per unit dose.
  • a unit may contain, for example, 0.5 mg to 1 g, preferably 1 mg to 700 mg, more preferably 5 mg to 100 mg of a compound of the invention (as a free-base, solvate (including hydrate) or salt, in any form), depending on the condition being treated, the route of administration, and the age, weight and condition of the patient.
  • Preferred unit dosage formulations are those containing a daily dose, weekly dose, monthly dose, a sub-dose or an appropriate fraction thereof, of an active ingredient.
  • formulations may be prepared by any of the methods well known in the pharmacy art.
  • compositions may be adapted for administration by any appropriate route, for example by the oral (including capsules, tablets, liquid- filled capsules, disintegrating tablets, immediate, delayed and controlled release tablets, oral strips, solutions, syrups, buccal and sublingual), rectal, nasal, inhalation, topical (including transdermal), vaginal or parenteral
  • formulations may be prepared by any method known in the art of pharmacy, for example by bringing into association the active ingredient with the carrier(s), excipient(s) or diluent.
  • the carrier, excipient or diluent employed in the pharmaceutical formulation is "non-toxic,” meaning that it/they is/are deemed safe for consumption in the amount delivered in the pharmaceutical composition, and "inert” meaning that it/they does/do not appreciably react with or result in an undesired effect on the therapeutic activity of the active ingredient.
  • compositions adapted for oral administration may be
  • the active drug component can be combined with an oral pharmaceutically acceptable carrier such as ethanol, glycerol, water and the like.
  • Powders are prepared by comminuting the compound to a suitable fine size and mixing with a similarly comminuted pharmaceutical carrier such as an edible carbohydrate, as, for example, starch or mannitol. Flavoring, preservative, dispersing and coloring agent can also be present.
  • Solid capsules are made by preparing a powder mixture, as described above, and filling formed gelatin sheaths.
  • Glidants and lubricants such as colloidal silica, talc, magnesium stearate, calcium stearate or solid polyethylene glycol can be added to the powder mixture before the filling operation.
  • disintegrating or solubilizing agent such as agar-agar, calcium carbonate or sodium carbonate can also be added to improve the availability of the medicament when the capsule is ingested.
  • disintegrating agents and coloring agents can also be incorporated into the mixture.
  • Suitable binders include starch, gelatin, natural sugars such as glucose or beta-lactose, corn sweeteners, natural and synthetic gums such as acacia, tragacanth or sodium alginate, carboxymethylcellulose, polyethylene glycol, waxes and the like.
  • Lubricants used in these dosage forms include sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride and the like.
  • Disintegrators include, without limitation, starch, methyl cellulose, agar, bentonite, xanthan gum and the like.
  • Tablets are formulated, for example, by preparing a powder mixture, granulating or slugging, adding a lubricant and disintegrant and pressing into tablets.
  • a powder mixture is prepared by mixing the compound, suitably comminuted, with a diluent or base as described above, and optionally, with a binder such as carboxymethylcellulose, an alginate, gelatin, or polyvinyl pyrrolidone, a solution retardant such as paraffin, a resorption accelerator such as a quaternary salt and/or an absorption agent such as bentonite, kaolin or dicalcium phosphate.
  • a binder such as carboxymethylcellulose, an alginate, gelatin, or polyvinyl pyrrolidone
  • a solution retardant such as paraffin
  • a resorption accelerator such as a quaternary salt
  • an absorption agent such as bentonite, kaolin or dicalcium phosphate.
  • the powder mixture can be granulated by wetting with a binder such as syrup, starch paste, acadia mucilage or solutions of cellulosic or polymeric materials and forcing through a screen.
  • a binder such as syrup, starch paste, acadia mucilage or solutions of cellulosic or polymeric materials and forcing through a screen.
  • the powder mixture can be run through the tablet machine and the result is imperfectly formed slugs broken into granules.
  • the granules can be lubricated to prevent sticking to the tablet forming dies by means of the addition of stearic acid, a stearate salt, talc or mineral oil.
  • the lubricated mixture is then compressed into tablets.
  • the compounds of the present invention can also be combined with a free flowing inert carrier and compressed into tablets directly without going through the granulating or slugging steps.
  • a clear or opaque protective coating consisting of a sealing coat of shellac, a coating of
  • Oral fluids such as solutions, syrups and elixirs can be prepared in dosage unit form so that a given quantity contains a predetermined amount of the compound.
  • Solutions and syrups can be prepared by dissolving the compound in a suitably flavored aqueous solution, while elixirs are prepared through the use of a pharmaceutically acceptable alcoholic vehicle.
  • Suspensions can be formulated by dispersing the compound in a
  • Solubilizers and emulsifiers such as ethoxylated isostearyl alcohols and polyoxy ethylene sorbitol ethers, preservatives, flavor additive such as peppermint oil or natural sweeteners or saccharin or other artificial sweeteners, and the like can also be added.
  • unit dosage formulations for oral administration can be microencapsulated.
  • the formulation can also be prepared to prolong or sustain the release as for example by coating or embedding particulate material in polymers, wax or the like.
  • the compounds of the invention can also be administered in the form of liposome delivery systems, such as small unilamellar vesicles, large unilamellar vesicles and multilamellar vesicles.
  • Liposomes can be formed from a variety of phospholipids, such as cholesterol, stearylamine or phosphatidylcholines.
  • the compounds of the invention may also be delivered by the use of monoclonal antibodies as individual carriers to which the compound molecules are coupled.
  • the compounds may also be coupled with soluble polymers as targetable drug carriers.
  • Such polymers can include
  • polyvinylpyrrolidone polyvinylpyrrolidone, pyran copolymer, polyhydroxypropyl- methacrylamidephenol, polyhydroxyethylaspartamidephenol, or
  • the compounds may be coupled to a class of biodegradable polymers useful in achieving controlled release of a drug, for example, polycentric acid, polepsilon caprolactone, polyhydroxy butyric acid, polyorthoesters, polyacetals, polydihydropyrans, polycyanoacrylates and cross-linked or amphipathic block copolymers of hydrogels.
  • a drug for example, polycentric acid, polepsilon caprolactone, polyhydroxy butyric acid, polyorthoesters, polyacetals, polydihydropyrans, polycyanoacrylates and cross-linked or amphipathic block copolymers of hydrogels.
  • Pharmaceutical formulations adapted for transdermal administration may be presented as discrete patches intended to remain in intimate contact with the epidermis of the recipient for a prolonged period of time.
  • the active ingredient may be delivered from the patch by iontophoresis as generally described in Pharmaceutical Research (1986) 3(6):318.
  • compositions adapted for topical administration may be formulated as ointments, creams, suspensions, lotions, powders, solutions, pastes, gels, sprays, aerosols or oils.
  • the formulations may be applied as a topical ointment or cream.
  • the active ingredient may be employed with either a paraffinic or a water-miscible ointment base.
  • the active ingredient may be formulated in a cream with an oil-in-water cream base or a water-in-oil base.
  • Pharmaceutical formulations adapted for topical may be formulated as ointments, creams, suspensions, lotions, powders, solutions, pastes, gels, sprays, aerosols or oils.
  • the formulations may be applied as a topical ointment or cream.
  • the active ingredient may be employed with either a paraffinic or a water-miscible ointment base.
  • the active ingredient may be formulated in a cream with an oil-in-
  • administrations to the eye include eye drops wherein the active ingredient is dissolved or suspended in a suitable carrier, especially an aqueous solvent.
  • a suitable carrier especially an aqueous solvent.
  • Pharmaceutical formulations adapted for topical administration in the mouth include lozenges, pastilles and mouth washes.
  • Pharmaceutical formulations adapted for rectal administration may be presented as suppositories or as enemas.
  • compositions adapted for nasal administration wherein the carrier is a solid include a coarse powder having a particle size for example in the range 20 to 500 microns which is administered in the manner in which snuff is taken, i.e. by rapid inhalation through the nasal passage from a container of the powder held close up to the nose.
  • Suitable formulations wherein the carrier is a liquid, for administration as a nasal spray or as nasal drops, include aqueous or oil solutions of the active ingredient.
  • Fine particle dusts or mists which may be generated by means of various types of metered dose pressurized aerosols, metered dose inhalers, dry powder inhalers, nebulizers or insufflators.
  • compositions adapted for vaginal administration may be presented as pessaries, tampons, creams, gels, pastes, foams or spray formulations.
  • compositions adapted for parenteral administration include aqueous and non-aqueous sterile injection solutions which may contain antioxidants, buffers, bacteriostats and solutes which render the formulation of pharmaceutically acceptable tonicity with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents.
  • the formulations may be presented in unit-dose or multi-dose containers, for example sealed ampoules and vials, and may be stored in a freeze-dried (lyophilized) condition requiring only the addition of the sterile liquid carrier, for example water for injection, immediately prior to use.
  • sterile liquid carrier for example water for injection
  • suspensions may be prepared from sterile powders, granules and tablets.
  • formulations may include other agents conventional in the art having regard to the type of formulation in question, for example those suitable for oral administration may include flavoring agents.
  • a compound of the invention may be employed alone, in combination with one or more other compounds of the invention or in combination with other therapeutic methods or agents.
  • combination with other chemotherapeutic, biologic, hormonal, antibody and supportive care agents is envisaged as well as combination with surgical therapy and radiotherapy.
  • Supportive care agents include analgesics, anti-emetics and agents used to treat heamatologic side effects such as neutropenia.
  • Analgesics are well known in the art.
  • Antiemetics include but are not limited to 5HT 3 antagonists such as ondansetron, granisetron, dolasetron, palonosetron and the like; prochlorperazine;
  • metaclopromide diphenhydramine; promethazine; dexamethasone;
  • lorazepam haloperidol
  • dronabinol dronabinol
  • olanzapine olanzapine
  • neurokinin-1 antagonists such as aprepitant, fosaprepitant and casopitant administered alone or in various combinations.
  • chemotherapeutic refers to any chemical agent having a therapeutic effect on the subject to which it is administered.
  • “Chemotherapeutic” agents include but are not limited to anti-neoplastic agents.
  • anti-neoplastic agents include both cytotoxic and cytostatic agents including biological, immunological and vaccine therapies.
  • Combination therapies according to the invention thus comprise the administration of at least one compound of the invention and the use of at least one other treatment method.
  • combination therapies according to the invention comprise the administration of at least one compound of the invention and surgical therapy.
  • combination therapies according to the invention comprise the administration of at least one compound of the invention and radiotherapy. In one
  • combination therapies according to the invention comprise the administration of at least one compound of the invention and at least one supportive care agent (e.g., at least one anti-emetic agent).
  • at least one supportive care agent e.g., at least one anti-emetic agent.
  • combination therapies according to the present invention comprise the administration of at least one compound of the invention and at least one other chemotherapeutic agent.
  • the invention comprises the administration of at least one compound of the invention and at least one anti-neoplastic agent.
  • the present invention provides the methods of treatment and uses as described above, which comprise administering a compound of the invention together with at least one chemotherapeutic agent.
  • the chemotherapeutic agent is an antineoplastic agent.
  • the invention provides a
  • compositions as described above further comprising at least one other chemotherapeutic agent, more particularly, the chemotherapeutic agent is an anti-neoplastic agent.
  • the invention also provides methods of treatment and uses as described above, which comprise administering a compound of the invention together with at least one supportive care agent (e.g., anti-emetic agent).
  • the compounds of the invention and at least one additional anti-neoplastic or supportive care therapy may be employed in combination concomitantly or sequentially in any therapeutically appropriate combination.
  • administration of a compound of the invention with one or more other antineoplastic agents may be in combination in accordance with the invention by administration concomitantly in one unitary pharmaceutical composition including both or all compounds or two or more separate pharmaceutical compositions each including one or more of the compounds.
  • components of the combination may be administered separately in a sequential manner wherein one active ingredient is administered first and the other(s) second or vice versa. Such sequential administration may be close in time or remote in time.
  • the dose of each compound may differ from that when the compound is used alone. Appropriate doses will be readily appreciated by those skilled in the art.
  • the appropriate dose of the compound(s) of the invention and the other therapeutically active agent(s) and the relative timings of administration will be selected in order to achieve the desired combined therapeutic effect, and are within the expertise and discretion of the attendant clinician.
  • any chemotherapeutic agent that has activity against a susceptible neoplasm being treated may be utilized in combination with the compounds of the invention, provided that the particular agent is clinically compatible with therapy employing a compound of the invention.
  • Typical anti-neoplastic agents useful in the present invention include, but are not limited to: alkylating agents, anti-metabolites, antitumor antibiotics, antimitotic agents,
  • topoisomerase I and II inhibitors include hormones and hormonal analogues;
  • retinoids include inhibitors of cell growth or growth factor function, angiogenesis inhibitors, and serine/threonine or other kinase inhibitors; cyclin dependent kinase inhibitors; antisense therapies and immunotherapeutic agents, including monoclonals, vaccines or other biological agents.
  • Alkylating agents are non-phase specific anti-neoplastic agents and strong electrophiles. Typically, alkylating agents form covalent linkages, by alkylation, to DNA through nucleophilic moieties of the DNA molecule such as phosphate, amino, and hydroxyl groups. Such alkylation disrupts nucleic acid function leading to cell death. Alkylating agents may be employed in combination with the compounds of the invention in the compositions and methods described above.
  • alkylating agents include but are not limited to nitrogen mustards such as cyclophosphamides, temozolamide, melphalan, and chlorambucil; oxazaphosphor-ines; alkyl sulfonates such as busulfan; nitrosoureas such as carmustine; triazenes such as dacarbazine; and platinum coordination complexes such as cisplatin, oxaliplatin and carboplatin.
  • Antimetabolite neoplastic agents are phase specific anti-neoplastic agents that act at S phase (DNA synthesis) of the cell cycle by inhibiting DNA synthesis or by inhibiting purine or pyrimidine base synthesis and thereby limiting DNA synthesis.
  • Antimetabolite neoplastic agents may be employed in combination with the compounds of the invention in the compositions and methods described above.
  • antimetabolite anti-neoplastic agents include but are not limited to purine and pyrimidine analogues and anti-folate compounds, and more specifically, hydroxyurea, cytosine, arabinoside, ralitrexed, tegafur, fluorouracil (e.g., 5FU), methotrexate, cytarabine, mecaptopurine and thioguanine.
  • Antitumor antibiotic agents are non-phase specific agents, which bind to or intercalate with DNA. Typically, such action disrupts ordinary function of the nucleic acids, leading to cell death. Antitumor antibiotics may be employed in combination with the compounds of the invention in the compositions and methods described above. Examples of antitumor antibiotic agents include, but are not limited to, actinomycins such as dactinomycin; anthracydines such as daunorubicin, doxorubicin, idarubicin, epirubicin and mitoxantrone;
  • Antimicrotubule or antimitotic agents are phase specific agents active against the microtubules of tumor cells during M or the mitosis phase of the cell cycle.
  • Antimitotic agents may be employed in combination with the compounds of the invention in the compositions and methods described above.
  • antimitotic agents include, but are not limited to, diterpenoids, vinca alkaloids, polo-like kinase (Plk) inhibitors and CenpE inhibitors. Examples of
  • diterpenoids include, but are not limited to, paclitaxel and its analog docetaxel.
  • vinca alkaloids include, but are not limited to, vinblastine, vincristine, vindesine and vinorelbine. Plk inhibitors are discussed further below.
  • Topoisomerase inhibitors include inhibitors of Topoisomerase II and inhibitors of Topoisomerase I.
  • Topoisomerase II inhibitors such as
  • epipodophyllotoxins are anti-neoplastic agents derived from the mandrake plant, that typically affect cells in the S and G2 phases of the cell cycle by forming a ternary complex with topoisomerase II and DNA, causing DNA strand breaks. The strand breaks accumulate and cell death follows.
  • Examples of epipodophyllotoxins include, but are not limited to, etoposide and teniposide.
  • Camptothecins including camptothecin and camptothecin derivatives, are available or under development as Topoisomerase I inhibitors.
  • Examples of camptothecins include, but are not limited to amsacrine, irinotecan, topotecan, and the various optical forms of 7-(4- methylpiperazino-methylene)-10,1 1 -ethylenedioxy-20-camptothecin.
  • Topoisomerase inhibitors may be employed in combination with the compounds of the invention in the compositions and methods described above.
  • Hormones and hormonal analogues are useful compounds for treating cancers in which there is a relationship between the hormone(s) and growth and/or lack of growth of the cancer.
  • Antitumor hormones and hormonal analogues may be employed in combination with the compounds of the invention in the compositions and methods described above.
  • hormones and hormonal analogues believed to be useful in the treatment of neoplasms include, but are not limited to antiestrogens, such as tamoxifen, toremifene, raloxifene, fulvestrant, iodoxyfene and droloxifene; anti- androgens; such as flutamide, nilutamide, bicalutamide and cyproterone acetate; adrenocorticosteroids such as prednisone and prednisolone;
  • antiestrogens such as tamoxifen, toremifene, raloxifene, fulvestrant, iodoxyfene and droloxifene
  • anti- androgens such as flutamide, nilutamide, bicalutamide and cyproterone acetate
  • adrenocorticosteroids such as prednisone and predni
  • aminoglutethimide and other aromatase inhibitors such as anastrozole, letrazole, vorazole, and exemestane
  • progestrins such as megestrol acetate
  • 5a-reductase inhibitors such as finasteride and dutasteride
  • gonadotropin-releasing hormones GnRH
  • analogues thereof such as Leutinizing Hormone-releasing Hormone (LHRH) agonists and antagonists such as goserelin luprolide, leuprorelin and buserelin.
  • LHRH Leutinizing Hormone-releasing Hormone
  • Retinoid(s) are compounds that bind to and activate at least one retinoic acid receptor selected from RARa, RAR , and RARy and/or compounds that bind to and activate at least one of RARa, RAR , and RARy and also at least one retinoic X receptor (RXR), including RXRa, RXR , and RXRy.
  • RXR retinoic X receptor
  • Retinoids for use in the present invention typically have affinity for RAR, and particularly for RARa and/or RAR .
  • certain synthetic retinoids, such as 9-cis- retinoic acid also have affinity for both RAR and RXR.
  • the retinoid has affinity for RARa (and RARa agonist).
  • retinoids examples include: retinoic acid; all-trans-retinoic acid (“ATRA” also known as “tretinoin”); tamibarotene (“Am80”); 9-cis-retinoic acid ((2E,4E,6Z,8E)-3,7-Dimethyl-9-(2,6,6-trimethylcyclohex-1 -enyl)nona- 2,4,6,8-tetraenoic Acid) (also known as “9-cis-Tretinoin”) (available from Sigma); Isotretinoin ((2Z,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethyl-1 - cyclohexenyl)nona-2,4,6,8-tetraenoic acid) (also known as "13-cis-retinoic acid”) (ACCUTANE®); Am580 (4-(5,6,7,8-tetrahydro-5,
  • TTNPB (4-[E-2-(5,6,7,8-Tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1 - propenyl]benzoic acid) (also known as "Ro 13-7410") See, M.F. Boehm et al. J. Med. Chem. 1994 37:2930 and R.P. Bissonnette et al., Mol. Cell. Biol.
  • RARa agonists known the art may also be used in the present invention.
  • Signal transduction pathway inhibitors are those inhibitors which block or inhibit a chemical process which evokes an intracellular change. As used herein these changes include, but are not limited to, cell proliferation or differentiation or survival.
  • Signal transduction pathway inhibitors useful in the present invention include, but are not limited to, inhibitors of receptor tyrosine kinases, non-receptor tyrosine kinases, SH2/SH3 domain blockers, serine/threonine kinases, phosphatidyl inositol-3-OH kinases, myoinositol signaling, and Ras oncogenes. Signal transduction pathway inhibitors may be employed in combination with the compounds of the invention in the compositions and methods described above.
  • protein tyrosine kinases catalyze the phosphorylation of specific tyrosine residues in various proteins involved in the regulation of cell growth.
  • protein tyrosine kinases can be broadly classified as receptor or nonreceptor kinases.
  • Receptor tyrosine kinase inhibitors which may be combined with the
  • growth factor receptor inhibitors include but are not limited to inhibitors of: insulin growth factor receptors (IGF-1 R, IR and IRR); epidermal growth factor family receptors (EGFR, ErbB2, and ErbB4); platelet derived growth factor receptors (PDGFRs), vascular endothelial growth factor receptors (VEGFRs), tyrosine kinase with immunoglobulin-like and epidermal growth factor homology domains (TIE-2), macrophage colony stimulating factor (c-fms), c-kit, c-met, fibroblast growth factor receptors (FGFRs), hepatocyte growth factor receptors (HGFRs), Trk receptors (TrkA, TrkB, and TrkC), ephrin (Eph) receptors and the RET protooncogene.
  • IGF-1 R insulin growth factor receptors
  • IR and IRR epidermal growth factor family receptors
  • PDGFRs platelet derived growth factor receptors
  • VEGFRs
  • Trastuzumab (Herceptin®) is an example of an anti-erbB2 antibody inhibitor of growth factor function.
  • An anti-erbB1 antibody inhibitor of growth factor function is cetuximab (ErbituxTM, C225).
  • Bevacizumab (Avastin®) is an example of a monoclonal antibody directed against VEGFR.
  • small molecule inhibitors of epidermal growth factor receptors include but are not limited to lapatinib (TykerbTM) and erlotinib (TARCEVA®). Imatinib
  • VEGFR inhibitors include pazopanib, ZD6474, AZD2171 , PTK787, sunitinib and sorafenib.
  • the invention provides methods of treatment of any of the various conditions enumerated above comprising administering a compound of the invention in combination with an EGFR or ErbB inhibitor.
  • the methods of the present invention comprise administering a compound of the invention in combination with lapatinib.
  • the methods of the present invention comprise administering a compound of the invention in combination with trastuzumab.
  • the methods of the present invention comprise administering a compound of the invention in combination with erlotinib.
  • the methods of the present invention comprise administering a compound of the invention in combination with gefitinib.
  • the present invention provides methods of treatment of any of the various conditions enumerated above comprising administering a compound of the invention in combination with a VEGFR inhibitor.
  • the methods of the present invention comprise administering a compound of the invention in combination with pazopanib.
  • Tyrosine kinases that are not transmembrane growth factor receptor kinases are termed non-receptor, or intracellular tyrosine kinases.
  • Inhibitors of nonreceptor tyrosine kinases are sometimes referred to as "anti-metastatic agents" and are useful in the present invention.
  • Targets or potential targets of anti-metastatic agents include, but are not limited to, c-Src, Lck, Fyn, Yes, Jak, Abl kinase (c-Abl and Bcr-AbI), FAK (focal adhesion kinase) and Bruton's tyrosine kinase (BTK).
  • Non-receptor kinases and agents, which inhibit nonreceptor tyrosine kinase function are described in Sinha, S. and Corey, S.J., (1999) J. Hematother. Stem Cell Res. 8:465-80; and Bolen, J.B. and Brugge, J.S., (1997) Annu. Rev. of Immunol. 15:371 -404.
  • SH2/SH3 domain blockers are agents that disrupt SH2 or SH3 domain binding in a variety of enzymes or adaptor proteins including, but not limited to, PI3-K p85 subunit, Src family kinases, adaptor molecules (She, Crk, Nek, Grb2) and Ras-GAP.
  • Src inhibitors include, but are not limited to, dasatinib and BMS-354825 (J.Med.Chem (2004) 47:6658-6661 ).
  • Inhibitors of serine/threonine kinases may also be used in combination with the compounds of the invention in any of the compositions and methods described above.
  • serine/threonine kinase inhibitors that may also be used in combination with a compound of the present invention include, but are not limited to, polo-like kinase inhibitors (Plk family e.g., Plk1 , Plk2, and Plk3), which play critical roles in regulating processes in the cell cycle including the entry into and the exit from mitosis; MAP kinase cascade blockers, which include other Ras/Raf kinase inhibitors, mitogen or
  • extracellular regulated kinases MEKs
  • extracellular regulated kinases ERKs
  • Aurora kinase inhibitors including inhibitors of Aurora A and Aurora B
  • protein kinase C (PKC) family member blockers including inhibitors of PKC subtypes (alpha, beta, gamma, epsilon, mu, lambda, iota, zeta);
  • IkB kappa-B
  • IKK-alpha IKK-beta
  • PKB/Akt kinase family inhibitors inhibitors of TGF-beta receptor kinases.
  • the present invention provides methods of treatment of any of the various conditions enumerated above comprising administering a compound of the invention in combination with a Plk inhibitor.
  • the methods of the present invention comprise administering a compound of the invention in combination with 5- ⁇ 6-[(4-Methylpiperazin-1 -yl)methyl]-1 H-benzimidazol-1 -yl ⁇ -3- ⁇ (1 R)-1 -[2- (trifluoromethyl)phenyl]ethoxy ⁇ thiophene-2-carboxamide.
  • Urokinase also referred to as urokinase-type Plasminogen Activator (uPA) is a serine protease. Activation of the serine protease plasmin triggers a proteolysis cascade which is involved in thrombolysis or extracellular matrix degradation. Elevated expression of urokinase and several other components of the plasminogen activation system have been correlated with tumor malignancy including several aspects of cancer biology such as cell adhesion, migration and cellular mitotic pathways as well. Inhibitors of urokinase expression may be used in combination with the compounds of the invention in the compositions and methods described above. Inhibitors of Ras oncogene may also be useful in combination with the compounds of the present invention.
  • inhibitors include, but are not limited to, inhibitors of farnesyltransferase, geranyl-geranyl transferase, and CAAX proteases as well as anti-sense oligonucleotides, ribozymes and immunotherapy. Such inhibitors have been shown to block Ras activation in cells containing mutant Ras, thereby acting as antiproliferative agents.
  • Inhibitors of kinases involved in the IGF-1 R signaling axis may also be useful in combination with the compounds of the present invention.
  • Such inhibitors include but are not limited to inhibitors of JNK1/2/3, PI3K, AKT and MEK, and 14.3.3 signaling inhibitors. Examples of AKT inhibitors are described in PCT Publication No. WO 2007/058850, published 24 May 2007 which corresponds to PCT Application No. PCT/US2006/043513, filed 9 Nov 2006.
  • AKT inhibitor disclosed therein is 4-(2-(4-amino-1 ,2,5-oxadiazol-3- yl)-1 -ethyl-7- ⁇ [(3S)-3-piperidinylmethyl]oxy ⁇ -1 H-imidazo[4,5-c]pyridin-4-yl)-2- methyl-3-butyn-2-ol .
  • Cell cycle signaling inhibitors including inhibitors of cyclin dependent kinases (CDKs) are also useful in combination with the compounds of the invention in the compositions and methods described above.
  • CDKs cyclin dependent kinases
  • Examples of cyclin dependent kinases, including CDK2, CDK4, and CDK6 and inhibitors for the same are described in, for instance, Rosania G. R., et al., Exp. Opin. Ther. Patents (2000) 10:215-230.
  • Receptor kinase angiogenesis inhibitors may also find use in the present invention. Inhibitors of angiogenesis related to VEGFR and TIE-2 are discussed above in regard to signal transduction inhibitors (both are receptor tyrosine kinases). Other inhibitors may be used in combination with the compounds of the invention.
  • anti-VEGF antibodies which do not recognize VEGFR (the receptor tyrosine kinase), but bind to the ligand; small molecule inhibitors of integrin (alpha v betas) that inhibit angiogenesis; endostatin and angiostatin (non-RTK) may also prove useful in combination with the compounds of the invention.
  • VEGFR antibody is bevacizumab (AVASTIN®).
  • Inhibitors of phosphatidyl inositol-3-OH kinase family members including blockers of PI3-kinase, ATM, DNA-PK, and Ku may also be useful in combination with the present invention.
  • myo-inositol signaling inhibitors such as phospholipase C blockers and myoinositol analogues.
  • siRNA, RNAi, locked nucleic acid polynucleotides, and antisense therapies may also be used in combination with the compounds of the invention.
  • antisense therapies include those directed towards the targets described above such as ISIS 2503 and gene therapy approaches such as those using thymidine kinase or cytosine deaminase.
  • Agents used in immunotherapeutic regimens may also be useful in combination with the compounds of the invention.
  • Immunotherapeutic regimens include ex-vivo and in-vivo approaches to increasing immunogenicity of patient tumor cells such as transfection with cytokines (eg. IL-2, IL-4, GMCFS and MCFS), approaches to increase T-cell activity, approaches with transfected immune cells and approaches with anti-idiotypic antibodies.
  • cytokines eg. IL-2, IL-4, GMCFS and MCFS
  • Another potentially useful immunotherapeutic regimen is monoclonal antibodies with wild-type Fc receptors that may illicit an immune response in the host (e.g., IGF-1 R monoclonal antibodies).
  • Agents used in proapoptotic regimens e.g., Bcl-2 antisense oligonucleotides
  • Bcl-2 antisense oligonucleotides may also be used in combination with the compounds of the invention.
  • Bcl-2 family of proteins block apoptosis. Upregulation of Bcl- 2 has therefore been linked to chemoresistance. Studies have shown that the epidermal growth factor (EGF) stimulates anti-apoptotic members of the Bcl-2 family (i.e., mcl-1 ). Therefore, strategies designed to downregulate the expression of Bcl-2 in tumors have demonstrated clinical benefit and are now in Phase ll/lll trials, namely Genta's G3139 bcl-2 antisense oligonucleotide. Such proapoptotic strategies using the antisense oligonucleotide strategy for Bcl-2 are discussed in Water, J.S., et al., J. Clin. Oncol. (2000) 18:1812-1823; and Kitada, S., et al., Antisense Res. Dev. (1994) 4:71 -79.
  • EGF epidermal growth factor
  • R 10 is halo (preferably chloro) or thiomethyl
  • E is a suitable carboxylic ester or carboxylic ester equivalent
  • R a is H or CH 3 ;
  • alk is alkyl or alkenyl
  • NBS N- bromosuccinimide
  • Compounds of formula (I) wherein R 4 is alkyl, haloalkyl, alkenyl, -R 11 -OR 12 , R 11 -CO 2 R 12 , -R 1 1 -SO 2 R 12 , -R 1 1 -Het1 or -R 11 -NR 12 R 13 may be prepared by reacting a compound of formula (VIII) with an alkyl or alkenyl metal reagent such as compounds having the formula Alk n MX m or X m MR 11 -CO 2 R 12
  • Alk is alkyl or alkenyl
  • n 1 , 2, 3 or 4;
  • M is a transition metal such as Zn, B or Sn;
  • X is halo, particularly CI or Br
  • n 0, 1 or 2;
  • R 4a is alkyl, haloalkyl, alkenyl, -R 11 -OR 12 , or R 11 -CO 2 R 12 ;
  • alkyl or alkenyl metal reagents include but not limited to dialkylzinc, alkylzinc halides, alkylboranes, alkenylboranes, alkenylborates and alkenylstannanes, either found commercially or which can be prepared by those of ordinary skill in the art by conventional means.
  • the reaction is performed in the presence of a palladium source, optionally a phosphine ligand and optionally a base in a suitable inert solvent.
  • Suitable palladium sources include but are not limited to bis(tri-t- butylphosphine)palladium (0), tris(dibenzylideneacetone)dipalladium (0), dichlorobis(triphenylphosphine)-palladium (II) or acetato(2'-di-f- butylphosphino-1 ,1 '-biphenyl-2-yl)palladium (II).
  • suitable phosphine ligands include but are not limited to 9,9-dimethyl-4,5- bis(diphenylphosphino)xanthene and triphenylphosphine.
  • Suitable bases include but are not limited to potassium acetate, cesium carbonate, sodium methoxide, and triethylamine.
  • suitable inert solvents include but are not limited to THF, toluene, ⁇ /,/V-dimethylformamide or 1 ,4-dioxane, or isopropanol in the case of alkenylborates.
  • the reaction may be carried out at a temperature of about 25 °C to 100°C.
  • a compound of formula (I 2 ) wherein R 4 is alkenyl may be converted to a compound of formula (I) wherein R 4 is -R 11 -SO 2 R 12 , -R 1 1 -Het1 or -R 11 - NR 12 R 13 by reaction with an appropriate nucleophile.
  • a compound of formula (I) wherein R 4 is -R 11 -SO 2 R 12 , or -R 11 NR 12 R 13 may be prepared by reacting a compound of formula (I 2 ) wherein R4 is alkenyl with a thiol or amine, respectively. Reaction conditions for such transformations are known to those skilled in the art.
  • Suitable alcohols include but not limited to methanol, ethanol, n-propanol or n-butanol.
  • the reaction may optionally be carried out in the presence of a base such as, but not limited to cesium carbonate, sodium methoxide, and triethylamine.
  • the reaction is typically carried out at a temperature of about 50-120 °C, at atmospheric or elevated pressure and optionally in a microwave.
  • R a is H or CH 3 and all other variables are as defined above.
  • R 10 is halo (preferably chloro)
  • the reaction is generally performed in a solvent or neat.
  • suitable solvents include but are not limited to isopropanol, methanol, 1 ,4-dioxane, ethanol, dimethylacetamide, triflouroethanol, and N,N- dimethylformamide.
  • the reaction is typically carried out at a temperature of from about 30 to about 120°C, or optionally in a microwave apparatus.
  • R 4 is NH 2
  • the reaction is carried out with a source of ammonia, for example, ammonia in methanol or preferably ammonium hydroxide.
  • the reaction is typically carried out without the addition of other solvents and at temperatures of about 60 °C to about 120 °C, in a sealed reaction vessel or optionally in a microwave apparatus.
  • appropriate protecting groups prior to reacting the compound of formula (VIII) with the compound of formula (IX).
  • R 4 is a group containing a pendant primary or secondary amine
  • the addition is preferably carried out when the pendant amine is protected as, for example, its corresponding t-butyl carbamate or trifluoracetamide.
  • the choice, installation and removal of appropriate protecting groups for reactions such as this is conventional in the art.
  • Compounds of formula (IX) are commercially available or may be synthesized using techniques conventional in the art.
  • the thiomethyl may first be converted to a more suitable leaving group, for example sulfoxide, sulfone, or chloride.
  • the thiomethyl can be converted into a sulfoxide or sulfone by oxidation with an appropriate oxidizing agent, for example oxone, sodium periodate, or meta- chloroperbenzoic acid, in an appropriate solvent, for example
  • reaction are generally performed in a suitable solvent, for example 2- propanol, dimethylacetamide, or dioxane, optionally with the addition of acid, for example hydrochloric acid, and at a temperature of 25-1 10°C, preferably 70-90°C, or in a microwave reactor at a temperature of 90-220°C, preferably 160-190°C.
  • a suitable solvent for example 2- propanol, dimethylacetamide, or dioxane
  • acid for example hydrochloric acid
  • the pyrimidinyl sulfoxide or sulfone can be converted to the corresponding hydroxyl pyrimidine by reaction with an appropriate aqueous acid, for example hydrochloric acid or acetic acid, at a temperature of 25- 1 10°C, preferably 70-90°C.
  • the hydroxyl pyrimidine can then be converted to a chloride using an appropriate chlorinating reagent, for example
  • Compounds of formula (VIII) may be prepared by reacting a compound of formula (XI) with a suitable brominating reagent, particularly bromine or NBS, followed by reacting with one of: 1 ) a thiourea, 2) a formamide 3) an amide 4) a thioamide or 5) a urea depending upon whether the thiazole or oxazole and
  • a suitable brominating reagent particularly bromine or NBS
  • thiourea unsubstituted thiourea, formamide, amide, thioamide or urea and substituted analogs thereof.
  • the thiourea, formamide, amide, thioamide or urea may be substituted with the desired group R 3 .
  • substituted analogs of thiourea, formamide, amide, thioamide or urea are commercially available or may be prepared using conventional techniques.
  • the reaction can be accomplished by the initial bromination of a compound of formula (XI) using an appropriate brominating reagent, for example bromine in solvent such as acetic acid or
  • the reaction is typically carried out in an appropriate solvent, for example dichloromethane, ⁇ , ⁇ -dimethylformamide, or ⁇ , ⁇ -dimethylacetamide, and at a temperature of 25-50°C, particularly 25°C.
  • the brominated analog i.e., a compound of formula (Xl-A)
  • thiourea an appropriately substituted thiourea
  • W is S
  • R 3a is -NR 12 R 13 or Het1 and all other variables are as defined above.
  • the reaction is typically carried out in an appropriate solvent, for example, N,N-dimethylformamide, ⁇ , ⁇ -dimethylacetamide, dichloromethane, tetrahydrofuran, dioxane, or acetonitrile, optionally in the presence of a suitable base, for example magnesium carbonate or sodium bicarbonate, and at a temperature of 25-90°C, particularly 25-50°C.
  • a suitable base for example magnesium carbonate or sodium bicarbonate
  • a compound such as a compound of formula (VIII), wherein R 3 is an amino group (i.e., -NR 12 R 13 ), may be further converted to a corresponding compound wherein R 3 is other than amino (or substituted amino) using the techniques described herein and those conventional in the art.
  • the aminothiazole compound of formula (Vlll-A) wherein R 3 is an amino group may be converted to an unsubstituted thiazole (i.e., a compound of formula (VIII) wherein R 3 is H) using methods familiar to those of skill in the art.
  • the thiazole may be prepared by reacting the aminothiazole with an appropriate reagent, for example i-butyl nitrite, in an appropriate solvent, for example tetrahydrofuran, and at a temperature of 35-75°C, particularly 40-60°C.
  • an aminothiazole of formula (VIII) may be modified according to methods that will be familiar to those skilled in the art.
  • the aminothiazole compound of formula (Vlll-A) may be converted to a compound of formula (Vlll-B) by reaction with reagents capable of replacing the amino group with a halide, preferably a bromide.
  • Hal is halo, preferably Br; and all other variables are as defined above.
  • the conversion to a halo-thiazole of formula (Vlll-B) may be carried out by reaction with for example, i-butyl nitrite and copper (II) bromide in a suitable solvent, such as tetrahydrofuran or acetonitrile, and at a temperature from - 10°C to 50°C, preferably 0°C to 25°C.
  • a suitable solvent such as tetrahydrofuran or acetonitrile
  • the halo-thiazole of formula (Vlll-B) may then be reacted under a variety of conditions known to those in the art to produce different thiazole compounds of formula (Vlll-C) wherein R 3 can be a variety of substituents consistent with the definition of R 3 in reference to compounds of Formula (I).
  • R 3c is alkyl, haloalkyl or alkyl-OH.
  • halo-thiazole of formula (Vlll-B) may be reacted with a boronic acid, boronate ester, alkyl tin, alkyl zinc or Grignard reagent, in an appropriate solvent, for example tetrahydrofuran, dioxane, or
  • palladiumdicholorobistriphenylphosphine and at a temperature of 25-150°C, preferably 25-60°C.
  • a suitable base such as aqueous sodium carbonate, cesium carbonate, or triethylamine
  • a suitable ligand for the palladium species for example a trialkylphosphine or a triarylphosphine, for example triphenylphosphine.
  • Another example of such a reaction involves the reaction of the halo-thiazole of formula (V-B) with a reagent capable of displacing the bromide, for example an amine, such as piperidine, methylamine, or methyl piperazine.
  • a reagent capable of displacing the bromide for example an amine, such as piperidine, methylamine, or methyl piperazine.
  • Hal is halogen
  • R 3d is -NR 12 R 13 ;
  • dimethylformamide at a temperature of 25°C to 150°C, preferably 50-90°C, optionally in the presence of a suitable acid, for example hydrochloric acid.
  • a compound of formula (Xl-A) is reacted with a thioamide, for example thio lkyl.
  • Alkyl substituted thioamides for use in this process are commercially available or may be prepared using conventional techniques.
  • the reaction is carried out in an appropriate solvent, for example, dichloromethane, tetrahydrofuran, dimethylformamide, ⁇ , ⁇ -dimethylacetamide, or acetonitrile, particularly dimethylformamide or ⁇ , ⁇ -dimethylacetamide, optionally in the presence of a suitable base, for example magnesium carbonate or sodium bicarbonate, and at a temperature of 35-100°C, preferably 50-80°C.
  • an appropriate solvent for example, dichloromethane, tetrahydrofuran, dimethylformamide, ⁇ , ⁇ -dimethylacetamide, or acetonitrile, particularly dimethylformamide or ⁇ , ⁇ -dimethylacetamide, optionally in the presence of a suitable base, for example magnesium carbonate or sodium bicarbonate, and at a temperature of 35-100°C, preferably 50-80°C.
  • reaction can be accomplished by reacting the compound of formula (Xl-A) with formamide in the presence of an acid, such as sulfuric acid, and at a temperature of 60-150°C, preferably 90-130°C.
  • an acid such as sulfuric acid
  • a substituted oxazole of formula (Vlll-F) may be prepared from the compound of form -A).
  • R 3e is Het1 or -NR 12 R 13 and all other variables are as defined above.
  • the reaction may be carried out by reacting the compound of formula (Xl-A) with urea or substituted urea in an appropriate solvent, for example, N,N- dimethylformamide, ⁇ /,/V-dimethylacetamide dichloromethane,
  • tetrahydrofuran, dioxane, or acetonitrile optionally in the presence of a suitable base, for example magnesium carbonate or sodium bicarbonate, and at a temperature of 25-170°C, particularly 60-150°C or in a microwave reactor at a temperature of 100-190°C, particularly 120-160°C.
  • a suitable base for example magnesium carbonate or sodium bicarbonate
  • substituted ureas that may be employed in the foregoing method to prepare compounds of formula (Vlll-F) wherein R 3e is as defined above.
  • a substituted urea for use in this method is 1 - pyrrolidinecarboxamide. Suitable substituted ureas are commercially available or can be made using techniques known to those skilled in the art.
  • a substituted oxazole of formula (Vlll-G), may also be prepared from a compound of formula (Xl-A).
  • reaction may be carried out by reacting the compound of formula (Xl-A) with an amide (i.e., a compound of formula R 3f -C(O)NH 2 ), for example acetamide, in an appropriate solvent, for example, dichloromethane, tetrahydrofuran, dimethylformamide, or acetonitrile, particularly
  • an amide i.e., a compound of formula R 3f -C(O)NH 2
  • an appropriate solvent for example, dichloromethane, tetrahydrofuran, dimethylformamide, or acetonitrile, particularly
  • dimethylformamide or neat optionally in the presence of a suitable base, for example magnesium carbonate or sodium bicarbonate, and at a temperature of 35-170°C, preferably 60-150°C or in a microwave reactor at a temperature of 100-190°C, particularly 130-170°C.
  • a suitable base for example magnesium carbonate or sodium bicarbonate
  • Suitable amides for use in this reaction will be apparent to those skilled in the art and are commercially available or may be prepared using conventional techniques.
  • Vlll-F oxazole of formula (Vlll-F) (wherein R 3 is an amine or substituted amino group)
  • R 3 is an amine or substituted amino group
  • Compounds of formula (XI) may be prepared by reacting a compound of formula (X) with a substituted pyrimidine of formula (III).
  • the reaction is generally performed by reacting a compound of formula (X) and a compound of formula (III) in the presence of a suitable base capable of deprotonating a compound of formula (III), for example lithium
  • a compound of formula (X) may be prepared by reacting the compound of formula (II) with a compound of formula (VII).
  • This reaction may be carried out using conditions conventional in the art for such coupling reactions, including the use of a solvent such as
  • Compounds of formula (II) wherein R 5 and R 6 are H are commercially available.
  • Compounds of formula (II) wherein one of R 5 and R 6 are halogen may be prepared by reduction of the compound of formula (XIII).
  • Appropriate conditions for the reduction reaction will be apparent to those skilled in the art and include palladium on carbon under a hydrogen atmosphere, sulfided platinum on carbon under a hydrogen atmosphere, or iron powder in acetic acid.
  • the reduction may be effected using Raney nickel under a hydrogen atmosphere.
  • the reaction may be carried out in an inert solvent at either atmospheric or elevated pressure. Suitable inert solvents include but are not limited to ethanol, methanol, and ethyl acetate.
  • Compounds of formula (XIII) may be prepared by oxidation of the compound of formula (XX) using an appropriate oxidizing agent such as but not limited to chromium trioxide or potassium permanganate to yield compounds of formula (XXI).
  • an appropriate oxidizing agent such as but not limited to chromium trioxide or potassium permanganate to yield compounds of formula (XXI).
  • the reaction is performed with chromium trioxide under strongly acidic conditions such as in the presence of sulfuric acid.
  • the reaction may be carried out at a temperature of about 80 °C to 100°C.
  • compounds of formula (II) wherein one of R 5 and R 6 are halogen may be prepared by reaction of the compound of formula (XV) with a nitrogen source such as benzophenone imine or t-butyl carbamate using conditions conventional in the art for Buchwald cross-coupling reactions.
  • a nitrogen source such as benzophenone imine or t-butyl carbamate
  • a palladium source optionally a phosphine ligand, and a base in a suitable inert solvent.
  • suitable palladium sources include but are not limited to tris(dibenzylideneacetone)dipalladium (0),
  • suitable phosphine ligands include but are not limited to 9,9-dimethyl-4,5- bis(diphenylphosphino)xanthene and triphenylphosphine.
  • suitable bases include but are not limited to potassium acetate, cesium carbonate, sodium methoxide, and triethylamine.
  • Suitable inert solvents include but are not limited to toluene, N,N-dimethylformamide or 1 ,4- dioxane.
  • the reaction may be carried out at a temperature of about 80 °C to 15 °C, optionally in the microwave.
  • X is halo, particularly Br
  • P is protected nitrogen, particularly benzophenone imine or t-butyl carbamate; and all other variables are as defined above.
  • Conversion of compounds of formula (XVI) to compounds of formula (II) can be achieved by reaction with a strong acid in a suitable organic solvent using conventional acidic deprotection techniques. Suitable acids used in such transformations include but are not limited to hydrochloric acid. Suitable solvents for such transformations include but are not limited to tetrahydrofuran and 1 ,4-dioxane. See, Kocienski, P.J. Protecting Groups, Georg Thieme Verlag, Stuttgart, 1994; and Greene, T.W., Wuts, P. G. M. Protecting Groups in Organic Synthesis (2 nd Edition), J. Wiley and Sons, 1991 .
  • R 10 is halo (preferably chloro) or thiomethyl
  • E is a suitable carboxylic ester or ester equivalent, particularly a methyl ester, ethyl ester, or Weinreb's amide;
  • Alloc is allylchlorofornnate
  • BusSnH is tri-n-butyl tin hydride
  • the installation and removal of the Alloc protecting group may be achieved using conventional means.
  • the compound of formula (II) may be reacted with allylchloroformate using conventional acylation conditions to those skilled in the art for the installation of carbamate protecting groups. Removal of the protecting group may be achieved by reacting the compound of formula (V) with tributyltin hydride in the presence of a Pd catalyst and weak acid.
  • dichlorobis(triphenylphosphine)-palladium (II) was used along with acetic acid.
  • solvents may be used including but not limited to dichloromethane, toluene, diethyl ether, acetone and N,N- dimethylformamide. See, Kocienski, P.J. Protecting Groups, Georg Thieme Verlag, Stuttgart, 1994; and Greene, T.W., Wuts, P. G. M. Protecting Groups in Organic Synthesis (2 nd Edition), J. Wiley and Sons, 1991 .
  • R 10 is halo (preferably chloro) or thiomethyl, and all other variables are as defined above.
  • a compound of formula (I) may be converted to another compound of formula (I) using techniques well known in the art.
  • compounds of formula (I) may be modified using conventional techniques to modify or diversify the groups defined by the variable R 3 and thereby provide different compounds of formula (I).
  • the present invention can readily convert a compound of formula (I) or a pharmaceutically acceptable salt thereof into a different compound of formula (I), or a pharmaceutically acceptable salt thereof.
  • the present invention also provides radiolabeled compounds of formula (I) and biotinylated compounds of formula (I) and solid-support-bound versions thereof, i.e.
  • Radiolabeled compounds of formula (I) and biotinylated compounds of formula (I) can be prepared using conventional techniques.
  • radiolabeled compounds of formula (I) can be prepared by reacting the compound of formula (I) with tritium gas in the presence of an appropriate catalyst to produce radiolabeled compounds of formula (I).
  • the compounds of formula (I) are tritiated.
  • the radiolabeled compounds of formula (I) and biotinylated compounds of formula (I) are useful in assays for the identification of compounds which inhibit at least one Raf family kinase, for the identification of compounds for the treatment of a condition capable of being treated with a Raf inhibitor, e.g., for the treatment of neoplasms susceptible to treatment with a Raf inhibitor.
  • the present invention also provides an assay method for identifying such compounds, which method comprises the step of specifically binding a radiolabeled compound of the invention or a biotinylated compound of the invention to the target protein or cellular homogenate. More specifically, suitable assay methods will include competition binding assays.
  • radiolabeled compounds of the invention and biotinylated compounds of the invention and solid-support-bound versions thereof can also be employed in assays according to the methods conventional in the art.
  • the following examples are intended for illustration only and are not intended to limit the scope of the invention in any way. The invention is defined by the claims which follow.
  • i. v. intravenous
  • ATP adenosine triphosphate
  • ml_ milliliters
  • BSA bovine serum albumin
  • ⁇ _ microliters
  • 45 CHCIs chloroform
  • mM millimolar
  • mCPBA metal-chloroperbenzoic mol (moles); acid
  • DCM CH 2 CI 2 ; dichloromethane
  • rt room temperature
  • DIEA ⁇ /,/V-Diisopropylethylamine
  • DME (1 ,2-dimethoxyethane); LDA (lithium diisopropylamide); DMEM (Dulbecco's modified ⁇ HMDS (lithium
  • Eagle medium Eagle medium
  • hexamethyldisilazide hexamethyldisilazide
  • DMF A/,dimethylformamide
  • LiOH lithium hydroxide
  • DMSO dimethylsulfoxide
  • LiOH H 2 O lithium hydroxide DPPA (diphenylphosphoryl azide); monohydrate
  • EDC ethylcarbodiimide m-CPBA (meta- hydrochloride); Chloroperoxybenzoic acid);
  • Et ethyl; -CH 2 CH 3
  • MgCO 3 magnesium carbonate
  • EtOH ethanol
  • MgSO 4 magnesium sulfate
  • EtOAc ethyl acetate
  • NaCI sodium chloride
  • HCI hydrochloric acid
  • NaHSO 4 sodium bisulfate
  • K2CO3 potassium carbonate
  • PE pertroleum ether
  • POCI3 phosporyl chloride
  • TBAB tetra butyl ammonium bromide
  • TBAF tetrabutylammonium fluoride
  • TFA trifluoroacetic acid
  • TIPS triisopropylsilyl
  • TMSE (2-(trimethylsilyl)ethyl); and TsOH (p-Toluenesulfonic acid).
  • MS mass spectra
  • MS-AX505HA Low-resolution mass spectra
  • Agilent LC/MSD SL JOEL SX-102
  • SCIEX-APIiii a Finnegan MSQ
  • Waters SQD Waters ZQ
  • Finnegan LCQ spectrometer high resolution MS were obtained using a JOEL SX-102A spectrometer.
  • All mass spectra were taken under electrospray ionization (ESI), chemical ionization (CI), electron impact (El) or by fast atom bombardment (FAB) methods.
  • ESI electrospray ionization
  • CI chemical ionization
  • El electron impact
  • FAB fast atom bombardment
  • Flash column chromatography was performed on silica gel (230-400 mesh, Merck) or using automated silica gel chromatography (Isco, Inc. Sq 16x or 100sg Combiflash) or (Analogix, Intelliflash).
  • Reported HPLC retention times (RT) were obtained on a Waters 2795 instrument attached to a Waters 996 diode array detector reading 210-500 nm or using Anilgent 120 series HPLC.
  • the column used was a Synergi Max-RP (50 x 2 mm) model #00B-4337-B0. Solvent gradient was 15% MeOH:water to 100% MeOH (0.1 % formic acid) over 6 min. Flow rate was 0.8 mL/min. Injection volume was 3 ⁇ .
  • Step 2 2-Propen-1 -yl ⁇ 3-[(2-chloro-4-pyrimidinyl)acetyl]-2- fluorophenyljcarbamate
  • reaction was quenched by the addition of the saturated aqueous NH CI (800 mL) at 0 °C.
  • the reaction mixture was extracted with EtOAc (1 L x 3). The combined organic layers were washed with water and brine successively, dried over Na2SO 4 , filtered and
  • the reaction mixture was quenched by adding saturated NaHCO3 (300 mL) slowly. The two layers were separated. The aqueous layer was extracted with DCM (1 L x 2). The combined organic layers were washed with water and brine successively, dried over Na 2 SO 4 , filtered and concentrated under reduced pressure. The crude product was washed with petroleum ether (500 mL) to afford the title compound.
  • Step 1 Methyl 2-chloro-3- ⁇ [ -propen-1 -yloxy)carbonyl]amino ⁇ benzoate
  • Step 3 2-Propen-1 -yl ⁇ 2-chloro-3-[5-(2-chloro-4-pyrimidinyl)-2-(4- morpholinyl)-1 ,3-thiazol-4-yl]phenyl ⁇ carbamate
  • Step 4 ⁇ 2-Chloro-3-[5-(2-chloro-4-pyrimidinyl)-2-(4-morpholinyl)-1 ,3-thiazol-4- yl]phenyl ⁇ amine
  • Step 1 2-Propen-1 -yl ⁇ 3-[5-(2-amino-4-pyrimidinyl)-2-(1 ,1 -dimethylethyl)- 1 ,3- thiazol-4-yl]-2-fluorophenyl ⁇ carbamate
  • Step 2 4-[4-(3-Amino-2-fluorophenyl)-2-(1 ,1 -dimethylethyl)-1 ,3-thiazol-5-yl]-2- py midinamine
  • Step 4 Methyl 2,6-difluoro-3- ⁇ [(2-propen-1 -yloxy)carbonyl]amino ⁇ benzoate
  • Step 5 2-Propen-1 -yl ⁇ 3-[(2-chloro-4-pyrimidinyl)acetyl]-2,4- difluorophenyljcarbamate
  • Step 6 2-Propen-1 -yl ⁇ 3-[5-(2-chloro-4-pynmidinyl)-2-(4-morpholinyl)-1 ,3- thiazol-4-yl]-2,4-difluorophenyl ⁇ carbamate
  • Step 7 3-[5-(2-Chloro-4-pyrimidinyl)-2-(4-morpholinyl)-1 ,3-thiazol-4-yl]-2,4- difluoroaniline
  • Step 1 Ethyl 3- ⁇ [(2-prope -1 -yloxy)carbonyl]amino ⁇ benzoate
  • Step 2 2-Propen-1 -yl ⁇ 3-[(2-chloro-4-pyrimidinyl)acetyl]phenyl ⁇ carbamate
  • Step 1 methyl 2-fluoro-3- ropylsulfonyl)amino]benzoate
  • Example 39 Following a procedure analogous to the one described in Example 39 using A/- ⁇ 2-chloro-3-[(2-chloro-4-pyhmidinyl)acetyl]phenyl ⁇ -1 -propanesulfonamide (1 .5 g, 3.86 mmol) in ⁇ /,/V-Dimethylacetamide (DMA) (7.73 ml) and treated with NBS (NBS (0.653 g, 3.67 mmol) to give the intermediate A/- ⁇ 3-[bromo(2- chloro-4-pyrimidinyl)acetyl]-2-chlorophenyl ⁇ -1 -propanesulfonamide.
  • DMA ⁇ /,/V-Dimethylacetamide
  • NBS NBS
  • Example 39 Following a procedure analogous to the one described in Example 39 using A/- ⁇ 3-[(2-chloro-4-pyrimidinyl)acetyl]-2-fluorophenyl ⁇ -1 -propanesulfonamide (1 .2 g, 3.23 mmol) in ⁇ /,/V-dimethylacetamide (DMA) (6.45 mL) to produce intermediate A/- ⁇ 3-[bromo(2-chloro-4-pyrimidinyl)acetyl]-2-fluorophenyl ⁇ -1 - propanesulfonamide.
  • DMA ⁇ /,/V-dimethylacetamide
  • a vessel was charged with a suspension of A/- ⁇ 2-chloro-3-[5-(2-chloro-4- pyrimidinyl)-2-(4-piperidinyl)-1 ,3-thiazol-4-yl]phenyl ⁇ -3,3,3-trifluoro-1 - propanesulfonamide (480 mg, 0.847 mmol) in 1 ,2-dichloroethane (DCE) (4237 ⁇ _).
  • DCE 1,2-dichloroethane
  • Step 1 - ⁇ [(1 ,1 -dimethylethyl)oxy]carbonyl ⁇ piperazin-1 -ium thiocyanate
  • Step 2 1 -dimethylethyl 4-(5-(2-chloro-4-pyrimidinyl)-4- ⁇ 2-fluoro-3- [(propylsulfonyl)amino]phenyl ⁇ -1 ,3-thiazol-2-yl)-1 -piperazinecarboxylate
  • a 100 mL round-bottomed flask was charged with A/- ⁇ 3-[(2-chloro-4- pyrimidinyl)acetyl]-2-fluorophenyl ⁇ -1 -propanesulfonamide (1 .5 g, 4.03 mmol) in A/,A/-dimethylacetamide (DMA) (13.45 ml) to give a brown solution at room temperature under nitrogen.
  • DMA A/,A/-dimethylacetamide
  • NBS (0.682 g, 3.83 mmol) was added to the reaction mixture.
  • the reaction mixture was stirred at room temperature for 1 h.
  • previously prepared boc-piperazinium thiocyanate salt from step 1 (0.990 g, 4.03 mmol) was added in one portion.
  • This reaction mixture was stirred at room temperature for 18 h before being diluted with water (20 mL) and EtOAc (25 mL). After decantation, the water layer was extracted with EtOAc (2 X 50 mL). The combined organic phases were washed with water (3 x 30 mL), dried over Na2SO4, filtered, and concentrated to dryness.
  • Step 1 2,2,5-trimethyl-1 ,3-dioxane-5-carboxylic acid
  • Step 2 2,2,5-trimethyl-1 ,3-dioxane-5-carboxamide
  • a vessel was charged with 2,2,5-trimethyl-1 ,3-dioxane-5-carboxylic acid (3.39 g, 19.46 mmol) and ⁇ , ⁇ '-carbonyldiimidazole (CDI) (3.79 g, 23.35 mmol) in tetrahydrofuran (THF) (64.9 mL) and stirred at room temperature for 1 .5h.
  • THF tetrahydrofuran
  • the solution was stirred at 0 °C for 30 min and then let warm up to room temperature overnight.
  • Step 3 2,2,5-trimethyl-1 ,3-dioxane-5-carbothioamide
  • a vessel was charged with 2,5-trimethyl-1 ,3-dioxane-5-carboxamide (2.65 g, 15.30 mmol) in tetrahydrofuran 20 ml_ and Lawesson's reagent (6.19 g, 15.30 mmol).
  • the reaction mixture was heated at reflux under nitrogen for 3h.
  • the reaction mixture was then allowed to stir at room temperature overnight before being concentrated under reduced pressure.
  • the residue was dissolved in EtOAc 200ml_ and washed with 10% NaHCO 3 and brine.
  • the organic phase was dried over MgSO 4 and evaporated to dryness.
  • reaction mixture was stirred at -10 °C for 30 min, and warmed to room temperature with stirring overnight.
  • the reaction mixture was cooled to 0°C and quenched by addition of the saturated aqueous NH CI (800ml).
  • the reaction mixture was extracted with ethyl acetate (800 mL x 3).
  • Example 1 A/- ⁇ 2-fluoro-3-[5-(2- ⁇ r2-(1 -pyrrolidinyl)ethyl1amino)-4-Pyrimidinyl)-2- (tetrahvdro-2H-pyran-4-yl)-1 ,3-thiazol-4-yllphenyl)-1 -propanesulfonamide
  • Example 2 A/- ⁇ 2-fluoro-3-[5-(2- ⁇ [2-( 1 -piperidinyl)ethyl1amino)-4-pyrimidinyl)-2- (tetrahvdro-2H-pyran-4-yl)-1 ,3-thiazol-4-yllphenyl)-1 -propanesulfonamide
  • Example 3 A/- ⁇ 3-[5-(2-amino-4-pyrimidinyl)-2-(tetrahvdro-2H-pyran-4-yl)-1 ,3- thiazol-4-yl1-2-fluorophenyl)-1 -propanesulfonamide
  • a 5 mL microwave tube was charged with A/- ⁇ 3-[5-(2-chloro-4-pyrimidinyl)-2- (tetrahydro-2H-pyran-4-yl)-1 ,3-thiazol-4-yl]-2-fluorophenyl ⁇ -1 - propanesulfonamide (250 mg, 0.503 mmol) and ammonium hydroxide (10 ml, 257 mmol) to give a yellow solution at room temperature under nitrogen.
  • the sealed reaction mixture was microwaved at 90°C for 1 h. After 1 h, the reaction mixture was concentrated.
  • Example 4 A/- ⁇ 2-fluoro-3-[5-(2- ⁇ [2-(4-methyl-1 -piperazinyl)ethyl1amino)-4- pyrimidinyl)-2-(tetrahvdro-2H-pyran-4-yl)-1 ,3-thiazol-4-yllphenyl)-1 - propanesulfonamide
  • Example 6 /V- ⁇ 2-fluoro-3-[5-(2- ⁇ [2-(4-morpholinyl)ethyl1amino)-4-pyhmidinyl)- 2- tetrahvdro-2H-pyran-4-yl)-1 ,3-thiazol-4-yllphenyl)-1 -propanesulfonamide
  • Example 7 A/-(2-fluoro-3-f5-(2-r(2-hvdroxyethyl)aminol-4-pyrimidinyl ⁇ -2- (tetrah dro-2H-pyran-4-yl)-1 ,3-thiazol-4-yllprienyl)-1-propanesulfonamide
  • Example 8 A/-(2-fluoro-3-r5-(2- ⁇ [(2R)-2-hvdroxypropynamino)-4-pyrimidinyl)-2- (4-morpholinyl)-1 ,3-thiazol-4-yllphenyl)-1 -propanesulfonamide
  • Example 10 A/- ⁇ 2-fluoro-3-r5-(2- ⁇ r(2S)-tetrahvdro-2-furanylmethyl1amino)-4- Pyrimidinyl)-2-(tetrahvdro-2H-pyran-4-yl)-1 ,3-thiazol-4-yllphenyl)-1 -
  • Example 1 1 A/- ⁇ 2-fluoro-3-r5-(2- ⁇ r(1 R)-2-hvdroxy-1 -methylethyl1amino)-4- pyrimidinyl)-2-(tetrahvdro-2H-pyran-4-yl)-1 ,3-thiazol-4-yllphenyl)-1 - propanesulfonamide

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des composés de sulfonamide-thiazole et sulfonamide-oxazole, des compositions contenant ceux-ci, ainsi que des procédés pour la préparation et des procédés pour leur utilisation en tant qu'agents pharmaceutiques.
PCT/US2010/051890 2009-11-10 2010-10-08 Composés de benzènesulfonamide-thiazole et oxazole Ceased WO2011059610A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP10830388.4A EP2498608A4 (fr) 2009-11-10 2010-10-08 Composés de benzènesulfonamide-thiazole et oxazole

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25976809P 2009-11-10 2009-11-10
US61/259,768 2009-11-10

Publications (1)

Publication Number Publication Date
WO2011059610A1 true WO2011059610A1 (fr) 2011-05-19

Family

ID=43991933

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/051890 Ceased WO2011059610A1 (fr) 2009-11-10 2010-10-08 Composés de benzènesulfonamide-thiazole et oxazole

Country Status (2)

Country Link
EP (1) EP2498608A4 (fr)
WO (1) WO2011059610A1 (fr)

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011161216A1 (fr) * 2010-06-25 2011-12-29 Novartis Ag Composés et compositions d'hétéroaryle en tant qu'inhibiteurs de protéine kinases
WO2012113774A1 (fr) 2011-02-24 2012-08-30 Nerviano Medical Sciences S.R.L. Dérivés de thiazolylphényl-benzènesulfonamido en tant qu'inhibiteurs de la kinase
WO2014194127A1 (fr) * 2013-05-30 2014-12-04 Plexxikon Inc. Composés pour modulation de kinases, et indications correspondantes
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
US9573969B2 (en) 2014-09-12 2017-02-21 Novartis Ag Compounds and compositions as kinase inhibitors
WO2018055097A1 (fr) 2016-09-23 2018-03-29 Cellipse Inhibiteurs de kinase lim, composition pharmaceutique et procédé d'utilisation dans des maladies induites par limk
CN111320548A (zh) * 2020-04-24 2020-06-23 浦拉司科技（上海）有限责任公司 抗癌药物中间体2-氟-3-氨基苯甲酸甲酯的合成方法
WO2020124397A1 (fr) * 2018-12-19 2020-06-25 Inventisbio Shanghai Ltd. Inhibiteurs de kinase src c-terminale
WO2021110997A1 (fr) * 2019-12-05 2021-06-10 INSERM (Institut National de la Santé et de la Recherche Médicale) Composés de n-(3-(5-(pyrimidin-4-yl)thiazol-4-yl)phényl)sulfonamide et leurs utilisations en tant qu'inhibiteurs de braf
CN114560774A (zh) * 2020-11-27 2022-05-31 瑞博(杭州)医药科技有限公司 一种2-氟-3-硝基苯甲酸的合成方法
CN115850103A (zh) * 2023-01-19 2023-03-28 北京颖泰嘉和生物科技股份有限公司 3-氨基-2-氟苯甲酸甲酯的制备方法
WO2023070076A1 (fr) * 2021-10-22 2023-04-27 The Board Of Trustees Of The University Of Illinois Composés contre les cancers provoqués par une mutation de braf
US12011449B2 (en) 2016-09-19 2024-06-18 Novartis Ag Therapeutic combinations comprising a c-RAF inhibitor
US12036227B2 (en) 2017-05-02 2024-07-16 Novartis Ag Combination therapy
US12187703B2 (en) 2019-05-13 2025-01-07 Novartis Ag Crystalline forms of N-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2 (trifluoromethyl)isonicotinamide as Raf inhibitors for the treatment of cancer
WO2025036387A1 (fr) * 2023-08-15 2025-02-20 沈阳中化农药化工研发有限公司 Procédé de préparation d'acide 2-fluoro-3-aminobenzoïque et de composés esters
WO2025036384A1 (fr) * 2023-08-15 2025-02-20 沈阳中化农药化工研发有限公司 Procédé de préparation d'acide 2-chloro-3-aminobenzoïque et composé ester de celui-ci

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009076140A1 (fr) * 2007-12-13 2009-06-18 Smithkline Beecham Corporation Inhibiteurs de kinase à base de thiazole et d'oxazole

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0411791D0 (en) * 2004-05-26 2004-06-30 Cyclacel Ltd Compounds
UA103319C2 (en) * 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009076140A1 (fr) * 2007-12-13 2009-06-18 Smithkline Beecham Corporation Inhibiteurs de kinase à base de thiazole et d'oxazole

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
See also references of EP2498608A4 *
TSAI ET AL.: "Discovery of a Selective Inhibitor of Oncogenic B-Raf Kinase with Potent Antimelanoma Activity.", PNAS, vol. 105, no. 8, 2008, pages 3041 - 3046, XP008155384 *

Cited By (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011161216A1 (fr) * 2010-06-25 2011-12-29 Novartis Ag Composés et compositions d'hétéroaryle en tant qu'inhibiteurs de protéine kinases
RU2606497C2 (ru) * 2011-02-24 2017-01-10 НЕРВИАНО МЕДИКАЛ САЙЕНСИЗ С.р.л. Тиазолилфенилбензолсульфонамидопроизводные в качестве ингибиторов киназ
WO2012113774A1 (fr) 2011-02-24 2012-08-30 Nerviano Medical Sciences S.R.L. Dérivés de thiazolylphényl-benzènesulfonamido en tant qu'inhibiteurs de la kinase
US9199979B2 (en) 2011-02-24 2015-12-01 Nerviano Medical Sciences S.R.L. Thiazolylphenyl-benzenesulfonamido derivatives as kinase inhibitors
US10709712B2 (en) 2013-03-14 2020-07-14 Novartis Ag Biaryl amide compounds as kinase inhibitors
US9694016B2 (en) 2013-03-14 2017-07-04 Novartis Ag Biaryl amide compounds as kinase inhibitors
US10245267B2 (en) 2013-03-14 2019-04-02 Novartis Ag Biaryl amide compounds as kinase inhibitors
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
US9873700B2 (en) 2013-05-30 2018-01-23 Plexxikon Inc. Compounds for kinase modulation, and indications therefor
CN105228983A (zh) * 2013-05-30 2016-01-06 普莱希科公司 用于激酶调节的化合物及其适应症
AU2014274093B2 (en) * 2013-05-30 2018-11-08 Plexxikon Inc. Compounds for kinase modulation, and indications therefor
JP2016520131A (ja) * 2013-05-30 2016-07-11 プレキシコン インコーポレーテッドＰｌｅｘｘｉｋｏｎ Ｉｎｃ． キナーゼ調節のための化合物、およびその適応
US10421761B2 (en) 2013-05-30 2019-09-24 Plexxikon Inc. Compounds for kinase modulation, and indications therefor
WO2014194127A1 (fr) * 2013-05-30 2014-12-04 Plexxikon Inc. Composés pour modulation de kinases, et indications correspondantes
US9573969B2 (en) 2014-09-12 2017-02-21 Novartis Ag Compounds and compositions as kinase inhibitors
US9809610B2 (en) 2014-09-12 2017-11-07 Novartis Ag Compounds and compositions as kinase inhibitors
US12011449B2 (en) 2016-09-19 2024-06-18 Novartis Ag Therapeutic combinations comprising a c-RAF inhibitor
WO2018055097A1 (fr) 2016-09-23 2018-03-29 Cellipse Inhibiteurs de kinase lim, composition pharmaceutique et procédé d'utilisation dans des maladies induites par limk
US12036227B2 (en) 2017-05-02 2024-07-16 Novartis Ag Combination therapy
CN113166136B (zh) * 2018-12-19 2024-03-01 益方生物科技(上海)股份有限公司 C端src激酶抑制剂
CN113166136A (zh) * 2018-12-19 2021-07-23 益方生物科技(上海)股份有限公司 C端src激酶抑制剂
US12427146B2 (en) 2018-12-19 2025-09-30 InventisBio Co., Ltd. C-terminal SRC kinase inhibitors
EP3898622A4 (fr) * 2018-12-19 2022-08-10 InventisBio Co., Ltd. Inhibiteurs de kinase src c-terminale
WO2020124397A1 (fr) * 2018-12-19 2020-06-25 Inventisbio Shanghai Ltd. Inhibiteurs de kinase src c-terminale
US12187703B2 (en) 2019-05-13 2025-01-07 Novartis Ag Crystalline forms of N-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2 (trifluoromethyl)isonicotinamide as Raf inhibitors for the treatment of cancer
CN114746419B (zh) * 2019-12-05 2023-10-24 国家医疗保健研究所 N-(3-(5-(嘧啶-4-基)噻唑-4-基)苯基)磺酰胺化合物及其用作braf抑制剂的用途
JP2023504730A (ja) * 2019-12-05 2023-02-06 アンセルム（アンスティチュート・ナシオナル・ドゥ・ラ・サンテ・エ・ドゥ・ラ・ルシェルシュ・メディカル） Ｎ－（３－（５－（ピリミジン－４－イル）チアゾール－４－イル）フェニル）スルホンアミド化合物及びｂｒａｆ阻害剤としてのそれらの使用
WO2021110997A1 (fr) * 2019-12-05 2021-06-10 INSERM (Institut National de la Santé et de la Recherche Médicale) Composés de n-(3-(5-(pyrimidin-4-yl)thiazol-4-yl)phényl)sulfonamide et leurs utilisations en tant qu'inhibiteurs de braf
CN114746419A (zh) * 2019-12-05 2022-07-12 国家医疗保健研究所 N-(3-(5-(嘧啶-4-基)噻唑-4-基)苯基)磺酰胺化合物及其用作braf抑制剂的用途
CN111320548B (zh) * 2020-04-24 2022-10-18 浦拉司科技（上海）有限责任公司 抗癌药物中间体2-氟-3-氨基苯甲酸甲酯的合成方法
CN111320548A (zh) * 2020-04-24 2020-06-23 浦拉司科技（上海）有限责任公司 抗癌药物中间体2-氟-3-氨基苯甲酸甲酯的合成方法
CN114560774B (zh) * 2020-11-27 2025-05-06 九洲药业(杭州)有限公司 一种2-氟-3-硝基苯甲酸的合成方法
CN114560774A (zh) * 2020-11-27 2022-05-31 瑞博(杭州)医药科技有限公司 一种2-氟-3-硝基苯甲酸的合成方法
WO2023070076A1 (fr) * 2021-10-22 2023-04-27 The Board Of Trustees Of The University Of Illinois Composés contre les cancers provoqués par une mutation de braf
CN115850103A (zh) * 2023-01-19 2023-03-28 北京颖泰嘉和生物科技股份有限公司 3-氨基-2-氟苯甲酸甲酯的制备方法
WO2025036387A1 (fr) * 2023-08-15 2025-02-20 沈阳中化农药化工研发有限公司 Procédé de préparation d'acide 2-fluoro-3-aminobenzoïque et de composés esters
WO2025036384A1 (fr) * 2023-08-15 2025-02-20 沈阳中化农药化工研发有限公司 Procédé de préparation d'acide 2-chloro-3-aminobenzoïque et composé ester de celui-ci

Also Published As

Publication number Publication date
EP2498608A1 (fr) 2012-09-19
EP2498608A4 (fr) 2013-04-24

Similar Documents

Publication Publication Date Title
EP2498608A1 (fr) Composés de benzènesulfonamide-thiazole et oxazole
EP2282636B1 (fr) Composés de benzène sulfonamide thiazole et oxazole
WO2009032667A1 (fr) Inhibiteurs de kinase à base de thiazole et d'oxazole
JP5561702B2 (ja) Ｐｉ３キナーゼ調節剤および使用方法
CA2758986C (fr) Inhibiteurs de la pi3 kinase et/ou du mtor
EP2406234A1 (fr) Inhibiteurs de thiazole sulfonamide et oxazole sulfonamide kinases
JP2011506454A (ja) チアゾールおよびオキサゾールキナーゼ阻害薬
HK1147907B (en) Benzene sulfonamide thiazole and oxazole compounds
HK1167862B (en) Inhibitors of pi3 kinase and / or mtor

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10830388

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2012537888

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2010830388

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP